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ABSTRACT 
 
Neuronal loss occurs in several neurodegenerative disorders, such as Alzheimer’s disease 
and Parkinson’s disease, as well as following acute insults, such as brain ischemia and trauma. 
In general, cell death can be categorized into two main types, apoptosis and necrosis, which are 
differentiated by distinct morphological and biochemical features. Cell death of neurons 
possesses special characteristics that are still inadequately understood. Deregulation of the 
cyclin-dependent kinase 5 (cdk5) has been suggested to have several consequences that might 
contribute to the course of neuronal death in both acute and chronic conditions. This 
deregulation could involve proteolytic cleavage of the cdk5 activator protein p35 to a p25-
fragment by the calcium-activated calpain-protease. Nevertheless, there are wide gaps in our 
understanding on the regulation of cdk5, which hampers the evaluation of the possible 
involvement of cdk5 in neuronal death. 
The aim of this study was to investigate the regulation of cdk5, in particular during the 
course of neuronal cell death, and also to evaluate the possible relationship between cdk5 and 
phosphorylation of the microtubule-associated protein tau. When cultured rat hippocampal 
neurons were subjected to various apoptosis-inducing compounds, one characteristic response 
was a decrease in the protein levels of p35, p25, and cdk5 as well as a reduction in the cdk5 
activity and tau phosphorylation. Toxicity caused by the neurotransmitter glutamate, or by 
calcium ionophores, was associated with a rapid calpain-mediated cleavage of p35, and an 
increase in the cdk5 activity. Unexpectedly, tau phosphorylation was concomitantly decreased. 
Both N-methyl-D-aspartate (NMDA) and non-NMDA classes of glutamate receptors were able 
to induce calpain-mediated p35 cleavage in the cultured neurons. However, the NMDA 
receptors predominantly mediated the effect of glutamate in neurons under normal culture 
conditions. A significant proportion of the p35 protein was detected in a phosphorylated state in 
rat brain tissue. Phosphorylation of p35 appeared to affect its proteolytic degradation by the 
proteasome, as well as the calpain-mediated cleavage of p35 to p25. 
In conclusion, the regulation of cdk5 is altered during the process of neuronal death. The 
neurotransmitter glutamate could be an especially relevant inducer of the putative cdk5-
associated mechanisms of cell death. However, the changes in cdk5 during neuronal death do 
not seem to be invariably linked to the phosphorylation status of tau protein. 
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1. INTRODUCTION 
 
Cell death occurs throughout the lifespan of multicellular organisms. Cell death is 
essential for many processes e.g. development, maintenance of tissue homeostasis, and 
for removal of damaged cells. Turnover of cells provides a means for regeneration in a 
number of different tissues. The existence of neuronal stem cells in adult brains 
indicates that also neurons can be replaced. However, the sophistication of the nervous 
system originates from the complex cellular architecture and functional properties 
established over a long period of time, starting well before birth. These features cannot 
be fully achieved by cells born later in life. For this purpose, the neuronal cells 
responsible for the elegance of the nervous system have a long lifespan allowing the 
cells to carry out their responsibilities throughout the life of the organism. 
 
Even though neurons are considered to be irreplaceable, there is significant neuronal 
death during the development of the nervous system, and death of neurons continues at 
low rate also throughout adulthood. This cell death does not compromise the 
functionality of the nervous system, as neurons are originally produced in excess, and 
the functions of the lost cells are often compensated by plastic changes in the remaining 
neurons. In some pathological conditions cell death can take place to such extent that 
the functionality of the system becomes impaired. Neuronal death can occur suddenly 
following acute insults such as ischemia or traumatic brain injury. Pathological cell 
death can also be slow and progressive as occurs in neurodegenerative disorders like 
Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis 
(ALS). The symptoms of these disorders often cause a major decline in independent 
functional capacity as well as in the quality of life, and lead to a long-term burden to the 
patients and their relatives. Furthermore, treatment of patients suffering from these 
disorders consumes a significant amount of health care resources.  
 
Research on the molecular mechanisms of cell death increases our understanding of 
basic biological processes, and provides a foundation for efforts aiming to prevent 
pathological cell death. As neurons generally cannot be replaced, finding ways to 
prevent neuronal death is of particular interest. The neuronal cells possess several 
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exceptional features, and therefore knowledge on the death of other cell types cannot be 
directly applied to neurons. Also neuronal death in different pathological conditions 
differs to such extent that understanding of the molecular events contributing to cell 
death in one disease cannot be extrapolated to other neurological conditions. The 
amount of information that can be obtained by studying neuronal death in human 
patients is restricted. Experimental modeling of various neuropathological conditions in 
laboratory animals, as well as in tissue and cell cultures, represents one possibility to 
considerably extend our knowledge on the cascades of molecular events ultimately 
leading to pathological neuronal death. The cyclin-dependent kinase 5 (cdk5) is one 
example of an enzyme that has been implicated in the molecular pathways underlying 
neuronal death. Cdk5 plays a pivotal role in the normal biology of neurons, however in 
some neuropathological conditions cdk5 has been suggested to become deregulated, and 
this may have pathological consequences. A detailed understanding on the regulation 
and functional significance of this enzyme is needed to dissect its possible contribution 
to pathological events. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Molecular mechanisms of neuronal cell death 
 
Cell death is often divided into two main types i.e. apoptotic and necrotic cell death. 
This distinction is classically made on the basis of morphological features, although also 
certain biochemical hallmarks are associated with different types of cell death 
(Syntichaki and Tavernarakis 2003, Yuan et al. 2003).  Apoptosis is an ordered and 
active “suicide” form of cell death, whereas necrosis represents a more uncontrolled and 
passive outcome of failed cell homeostasis (Orrenius et al. 2003, Yuan et al. 2003). 
Frequently cell death occurs in a manner that cannot be classified as being purely 
apoptotic or necrotic. Sometimes the features of cell death differ so extensively from 
these two main types, that additional classifications are used. For example, destruction 
of the cell by its own lysosomal system has been suggested to represent a special form 
of cell death, i.e. autophagic cell death (Yuan et al. 2003, Assuncao Guimaraes and 
Linden 2004). Excitotoxic cell death is a form of cell death that is characterized by its 
distinct cell death-inducing stimulus. Neuronal cell death as a result of excitotoxicity is 
of particular importance, since this kind of cell death is involved in many pathological 
conditions of the nervous system (Lipton and Rosenberg 1994). 
 
2.1.1. Necrotic cell death 
 
Necrotic cell death has been traditionally regarded as a chaotic breakdown of cells 
occurring under intolerable conditions. However, recent studies have revealed, that 
similarly as previously observed in apoptosis, also necrosis seems to involve a limited 
number of biochemical cascades, although there is no molecular machinery especially 
evolved for this purpose (Syntichaki and Tavernarakis 2003, Yuan et al. 2003). Rather 
the cell death-inducing stimuli lead to destabilization of normal cellular activities. Once 
disturbed, these normal physiological processes become destructive and promote a 
cascade of events leading to cell death (Syntichaki and Tavernarakis 2003, Yuan et al. 
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2003). Necrosis usually takes place as a result of severe injury. Nevertheless, there are 
also several examples of necrotic cell death occurring during the normal course of 
development and tissue regulation (“programmed cell death”, PCD) (Proskuryakov et 
al. 2003, Assuncao Guimaraes and Linden 2004, Edinger and Thompson 2004).  
 
The morphological characteristics of necrosis include clumping of chromatin without 
any marked changes in its distribution, swelling of mitochondria, and local disruption of 
cellular membranes. Subsequently there is pronounced disintegration of organelles and 
membranes, disappearance of chromatin, and cell lysis (Lossi and Merighi 2003, Yuan 
et al. 2003). Generally necrosis involves a large number of cells that are often grouped 
together. As the contents of the cells are released into the surrounding tissue, necrosis is 
associated with an inflammatory response. The remains of the necrotic cells are 
eventually removed by phagocytosis (Lossi and Merighi 2003). 
 
Perturbation of cellular ion homeostasis, especially calcium homeostasis, has been 
closely linked with necrotic cell death. However, calcium-involving mechanisms are not 
specific for necrosis, as calcium is commonly associated with apoptosis as well (Leist 
and Nicotera 1999, Syntichaki and Tavernarakis 2003, Yuan et al. 2003). Normally 
calcium functions as a ubiquitous intracellular messenger, controlling the activity of a 
number of enzymes, ion channels, etc. The level of intracellular calcium is actively kept 
low when compared to the extracellular space and to the calcium stores within the 
endoplasmic reticulum (Alberts et al. 2002, Orrenius et al. 2003, Syntichaki and 
Tavernarakis 2003). Activation of calcium channels on the plasma membrane or in the 
endoplasmic reticulum leads to local elevations in the level of intracellular calcium. The 
mitochondria can buffer the intracellular calcium level by taking up the cation when the 
intracellular calcium concentration is high (Alberts et al. 2002, Syntichaki and 
Tavernarakis 2003, Duchen 2004). However abnormally intense calcium-mediated 
signaling can lead to pronounced activation of several cell death-associated enzymes 
such as proteases (calpain), lipases (phospholipase A2), nitric oxide synthase (NOS), 
kinases (protein kinase C), and phosphatases (calcineurin). Calcium also can evoke cell 
death via its effects on the mitochondria (Leist and Nicotera 1999, Orrenius et al. 2003, 
Wu et al. 2004). 
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Several proteases are known to be involved in necrotic cell death. Induction of the 
calcium-activated calpain proteases frequently occurs during necrosis (Wang 2000, 
Syntichaki and Tavernarakis 2003). One important group of necrosis-associated calpain 
targets are the cytoskeletal proteins, such as αII-spectrin, the microtubule-associated 
protein tau, and tubulin (Wang 2000, Rami 2003). During necrosis, also the lysosomal 
cathepsin proteases can leak into the cytosol, possibly due to calpain-mediated 
destabilization of lysosomal membrane integrity, or following damage to the lysosomal 
membranes by free radicals (Nakanishi 2003, Syntichaki and Tavernarakis 2003). Also 
the caspase proteases, traditionally associated with apoptotic cell death, can be activated 
during necrosis. This possibly occurs due to leakage of caspase activating factors from 
damaged mitochondria, or by calpain or cathepsin mediated cleavage. Indeed, a 
complex cascade of protease activation may take place also during necrosis (Syntichaki 
and Tavernarakis 2003). 
 
The mitochondria are the major source of ATP within the cell. Disturbed mitochondrial 
function, such as that commonly occurring during necrosis, leads to depletion of energy, 
as well as to production of reactive oxygen species (ROS). Leakage of electrons from 
the mitochondrial electron transport chain promotes formation of ROS such as 
superoxide ions (O2-) and H2O2 (Proskuryakov et al. 2003, Duchen 2004). Another 
cellular ROS is nitric oxide, a diffusible free radical second messenger, produced by the 
enzyme, NOS. Importantly, the neuronal NOS isoform (nNOS) is regulated in a 
calcium-dependent manner (Davis et al. 2001, Duchen 2004). Excessive levels of ROS 
can induce damage to proteins, lipids, and nucleic acids. In mitochondria, ROS, 
especially when combined with an elevated level of intracellular calcium, contribute to 
cell death by promoting the opening of a non-specific mitochondrial pore, called the 
permeability transition pore (PTP) (Orrenius et al. 2003, Duchen 2004, Gunter et al. 
2004). Opening of the PTP results in mitochondrial depolarization, and subsequently to 
increased permeability of the outer mitochondrial membrane such that even large for 
protein molecules can leak into the cytosol (Gulbins et al. 2003, Duchen 2004). 
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2.1.2. Apoptotic cell death 
 
Apoptosis was originally described as cell death characterized morphologically by 
cellular shrinkage in the presence of maintained organelle integrity, condensation of 
nuclear chromatin, plasma membrane blebbing, cellular fragmentation, and 
phagocytosis of the remaining apoptotic bodies by neighboring cells (Kerr et al. 1972). 
Later, also certain biochemical hallmarks of apoptosis, such as activation of caspase-
proteases and oligonucleosomal cleavage of chromatin, have been described (Zakeri and 
Lockshin 2002, Friedlander 2003, Edinger and Thompson 2004). The majority of PCD 
occurs by apoptosis, and it is frequently detected also in pathological situations 
(Friedlander 2003, Lossi and Merighi 2003). 
 
Apoptosis is an active process requiring energy and usually also synthesis of new 
proteins. Apoptosis can be triggered be several factors e.g. external death-promoting 
factors, loss of external factors needed for survival, or signs of internal damage (Creagh 
et al. 2003, Benn and Woolf 2004). The initial intracellular events involved in 
transmitting and modulating the apoptosis-promoting signals vary considerably 
depending on many factors as the initial stimulus and the cell type. Changes in calcium 
signaling, ROS production, kinase activities, gene expression, and mitochondrial 
function commonly take place (Friedlander 2003, Benn and Woolf 2004). Nevertheless, 
the downstream cellular machinery which integrates the pro-apoptotic and anti-
apoptotic signals, and subsequently executes the apoptotic program, is quite stereotypic 
and rather well conserved during evolution (Creagh et al. 2003, Friedlander 2003, Lossi 
and Merighi 2003, Yuan et al. 2003). Once the critical executioners of apoptosis have 
been activated, the process continues by ordered degradation of DNA into 
oligonucleasomal fragments, and disassembly of cellular structures. Since the remains 
of the cells are removed by phagocytosis and the cellular contents are not released to the 
surrounding tissue, there is no inflammation associated with apoptotic cell death 
(Creagh et al. 2003, Friedlander 2003, Assuncao Guimaraes and Linden 2004). 
 
Activation of the caspase family of proteases (cysteine-dependent aspartate-specific 
proteases) is regarded as being an important step in the commitment to apoptotic cell 
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death (Creagh et al. 2003, Sprick and Walczak 2004). The caspases constitute a step 
where the best established apoptosis-associated biochemical pathways converge, 
although it should be noted that the caspases can also be bypassed during the course of 
apoptosis (Orrenius et al. 2003, Assuncao Guimaraes and Linden 2004). The caspases 
exist in the cytosol as inactive zymogens (procaspases), and the upstream initiator 
caspases (caspase-2, -8, -9, and -10) are activated as a result of pro-apoptotic signaling. 
Once activated, the initiator caspases activate the downstream effector caspases 
(caspase-3, -6, and -7) in a cascade-like manner (Creagh et al. 2003, Sprick and 
Walczak 2004). The effector caspases themselves cleave key enzymes, structural 
proteins, and regulatory proteins, in addition to activating additional destructive 
enzymes (Earnshaw et al. 1999, Creagh et al. 2003). The most widely recognized 
pathways leading to caspase activation, e.g. the mitochondrial pathway activating 
caspase-9, and the death receptor pathway involving caspase-8, are briefly described 
below.  
 
The mitochondria have a key role in integrating pro- and anti-apoptotic signals from a 
variety of sources. The balance between pro-apoptotic (e.g. Bax, Bak, Bid, Bad, Bim) 
and anti-apoptotic (e.g. Bcl-2 and Bcl-xL) members of the Bcl-2 family of proteins 
contributes to the control of the mitochondrial PTP (Bortner and Cidlowski 2002, 
Akhtar et al. 2004, Benn and Woolf 2004, Green and Kroemer 2004). Once the PTP is 
opened, there is an increase in the permeability of the outer mitochondrial membrane, 
and release of several pro-apoptotic proteins from the mitochondria (Gulbins et al. 
2003, Hajnoczky et al. 2003, Benn and Woolf 2004). When cytochrome c, a member of 
the mitochondrial electron transport chain, is released into the cytosol, it forms a 
complex called the apoptosome together with apoptosis protease-activating factor-1 
(Apaf-1), procaspase-9, and dATP. This complex activates caspase-9, leading to 
induction of downstream caspases (Friedlander 2003, Gulbins et al. 2003, Benn and 
Woolf 2004). Apoptosis induced by many stress stimuli involve mitochondria at an 
early stage. The stimuli can alter the balance between pro- and anti-apoptotic Bcl-2 
family proteins, by affecting gene expression or by inducing changes at the protein level 
(e.g. by protein-protein interactions, altered phosphorylation, or by proteolysis) 
(Gulbins et al. 2003, Akhtar et al. 2004, Benn and Woolf 2004). Several stress stimuli 
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can also increase the concentration of intracellular free calcium, as frequently occurs 
during apoptosis. Excessive influx of calcium to the mitochondria promotes opening of 
the PTP, disruption of mitochondrial membrane potential, and the generation of  ROS 
(Hajnoczky et al. 2003, Orrenius et al. 2003). 
 
Some members of the tumor necrosis factor (TNF) receptor superfamily are called death 
receptors (DRs) due to their ability to activate pro-apoptotic intracellular signaling. 
These receptors include Fas, TNFR1, DR3, DR4, DR5, and DR6 (Curtin and Cotter 
2003). Once the ligand binds to its binding site, the receptors oligomerize, and recruit an 
intracellular signaling complex, promoting activation of procaspase-8 (Curtin and 
Cotter 2003, Benn and Woolf 2004, Sprick and Walczak 2004). In some cell types, the 
activation of the caspase-8 is sufficient to activate downstream effector caspases. In 
other cell types, activation of caspase-8 leads to cleavage of the Bcl-2 family member 
Bid, which promotes apoptosis through the mitochondrial apoptotic pathway (Scaffidi et 
al. 1998, Curtin and Cotter 2003, Benn and Woolf 2004, Sprick and Walczak 2004). 
Activation of death receptors is a common trigger of PCD in different tissues. With 
respect to neuronal cells, up-regulation of Fas-ligand expression occurs in response to a 
deficiency of neurotrophic factors, and Fas activation seems to be obligatory for 
apoptosis induced by trophic factor deprivation in several types of neuronal cells (Le-
Niculescu et al. 1999, Raoul et al. 1999).  
 
Although necrosis and apoptosis have been classically regarded as distinct and separate 
processes, there does appear to be a partial overlap in the molecular mechanisms 
underlying these two types of cell death. Whether the partly shared biochemical 
processes give rise to an apoptotic or necrotic morphological pattern, may be 
determined by factors like the intensity and duration of the original stimulus (Bonfoco 
et al. 1995, Syntichaki and Tavernarakis 2003, Benn and Woolf 2004). The 
mitochondria are believed to play an important role in the decision making process. It 
has been proposed that opening of the mitochondrial PTP only in a few mitochondria 
would result in lysosomal degradation of the affected mitochondria by autophagy. 
However, when more mitochondria become involved, the process would culminate in 
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apoptosis, and when the PTP opens in virtually all mitochondria of the cell, the result 
would be profound depletion of ATP followed by necrosis (Lemasters et al. 1998). 
 
2.1.3. Autophagic cell death 
 
The term autophagy refers to a process where a proportion of the cellular cytoplasm is 
engulfed into a double-membrane vesicle, and the resulting autophagosome is 
subsequently fused with a lysosome to permit degradation of its contents by lysosomal 
hydrolytic enzymes (Yuan et al. 2003, Marino and Lopez-Otin 2004, Shintani and 
Klionsky 2004). Autophagy occurs as a means to resist starvation, as well as for 
degradation of dysfunctional organelles and other cytoplasmic components (Yuan et al. 
2003, Marino and Lopez-Otin 2004, Shintani and Klionsky 2004). Additionally, 
extensive autophagy may lead to a special form of cell death, i.e. autophagic cell death. 
 
The most prominent feature of autophagic cell death is the appearance of large 
autophagic vacuoles. When most of the cytoplasm has been destroyed by autophagy, 
there is induction of apoptotic markers and phagocytosis of the cell remnants as in 
classical apoptosis. However, the apoptotic phase of cell death is short and markedly 
delayed (Clarke 1990, Zakeri and Lockshin 2002). The induction of autophagy appears 
to be regulated by the phosphatidylinositol-3-kinases (PI3Ks) though other factors are 
also involved. In nutrient rich conditions, signaling involving class I PI3K and the Akt-
kinase can activate mTor, which arrests autophagy. During starvation, this pathway is 
inhibited, whereas the activity of class III PI3K promotes membrane events associated 
with autophagosome formation (Marino and Lopez-Otin 2004, Shintani and Klionsky 
2004). There are several examples of cell death involving autophagic events in the 
absence of any significant apoptotic features. Also, in some cases cell death is reduced 
in cultured cells when autophagy is inhibited (Assuncao Guimaraes and Linden 2004, 
Marino and Lopez-Otin 2004). However, there is still debate on whether autophagy 
produces a special form of cell death, or is merely a non-causative, or even survival-
promoting, phenomenon occurring during cell death in some stressful conditions (Yuan 
et al. 2003, Edinger and Thompson 2004). Future research on autophagy will provide 
better tools to be used in the evaluation of the role of autophagy in cell death. 
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2.1.4. Glutamate excitotoxicity 
 
The term excitotoxicity refers to toxicity caused by abnormally intense stimulation of 
receptors activated by excitatory neurotransmitters. Glutamate is the major mediator of 
excitatory neurotransmission in the brain, and therefore it is not surprising, that 
glutamate is also the most important inducer of excitotoxicity (Dingledine et al. 1999, 
Arundine and Tymianski 2003). Glutamate excitotoxicity frequently occurs following 
acute insults such as brain ischemia, trauma, or epileptic seizures, and it is believed to 
be involved also in several neurodegenerative disorders (Lipton and Rosenberg 1994). 
Glutamate excitotoxicity may take place when the level of extracellular glutamate is 
elevated due to increased release, or decreased uptake of the neurotransmitter. Cell 
death due to glutamate excitotoxicity can occur with both necrotic and apoptotic 
mechanisms (Bonfoco et al. 1995, Lankiewicz et al. 2000, Zipfel et al. 2000). 
 
The cellular effects of glutamate are mediated by three different classes of ionotropic 
glutamate receptors, as well as by metabotropic glutamate receptors (mGluRs) (Siegel et 
al. 1999, Arundine and Tymianski 2003). In general, the ionotropic receptors have an 
agonist-binding site and the associated ion channel in the same macromolecular 
complex. The ionotropic α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA), and kainate classes of glutamate receptors are collectively called “non-
NMDA” receptors due to their structural similarity and overlapping pharmacological 
properties. Binding of glutamate to the extracellular part of the receptor opens the 
receptor ion channel. However the ion fluxes are soon terminated by a conformational 
change occurring in the receptor (desensitization) (Dingledine et al. 1999, Siegel et al. 
1999). At the normal resting potential, the N-methyl-D-aspartate (NMDA) class of 
ionotropic glutamate receptors do not efficiently respond to glutamate due to blockage 
of the receptor ion channel by a magnesium ion. When the plasma membrane is 
depolarized, for instance due to high activity of the non-NMDA receptors, the 
magnesium block of the NMDA receptors is removed, and the receptor becomes 
permeable to ions (Kandel et al. 1995, Dingledine et al. 1999, Siegel et al. 1999). The 
mGluRs are structurally and functionally distinct from the ionotropic receptors. The 
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mGluRs are G-protein coupled receptors, and they mediate their effect by affecting 
intracellular signaling molecules, such as phospholipase C or adenylyl cyclase, rather 
than by directly controlling the activity of ion channels (Siegel et al. 1999). 
 
As described in the previous chapters, excessive increase in the level of intracellular 
calcium activates several downstream events, which contribute to both necrotic and 
apoptotic cell death. In glutamate excitotoxicity, the role of calcium is critical (Choi 
1987). The post-synaptic signaling induced by glutamate receptor activation results in 
an increased intracellular calcium level via several different mechanisms. Activation of 
the non-NMDA receptors leads to influx of sodium causing depolarization. However, 
some non-NMDA receptors are also permeable to calcium (Tanaka et al. 2000, 
Arundine and Tymianski 2003). The glutamate-induced depolarization also leads to 
calcium influx due to opening of voltage-sensitive calcium channels (VSCC) in the 
plasma membrane (Leist and Nicotera 1999, Arundine and Tymianski 2003). Under 
depolarized conditions, glutamate activates also the NMDA receptors. These receptors 
cause further sodium influx, and are potent activators of calcium-dependent intracellular 
signaling due to their high calcium permeability (Kandel et al. 1995, Aarts and 
Tymianski 2003, Arundine and Tymianski 2003). The mGluRs are also able to increase 
the level of intracellular calcium by provoking mobilization of calcium from the 
endoplasmic reticulum (Siegel et al. 1999). The quantity of calcium influx alone does 
not seem to predict the extent of cell death. Also the route of calcium influx may 
determine whether the excitotoxicity-associated events take place. Calcium influx 
through the NMDA receptors is considered to be particularly important with respect to 
glutamate excitotoxicity, possibly due to the close association of the receptors with 
certain mediators of calcium-activated signaling, such as nNOS (Sattler et al. 1998, 
Arundine and Tymianski 2003, Duchen 2004). However, in some conditions also the 
AMPA receptors may play a predominant role. 
 
2.1.5. Cell death in disorders of the nervous system 
 
Neuronal cell death is a feature of several neuropathological conditions. After acute 
insults, such as stroke, traumatic brain injury, or epileptic seizures, there is immediate 
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and extensive loss of neurons followed by delayed cell death when cells are lost at a 
slower rate. Also several neurodegenerative disorders, such as AD, PD, ALS, or 
Huntington’s disease, are characterized by neuronal loss, which generally occurs in a 
slow and progressive manner. Cell death occurring under these conditions, especially in 
stroke and neurodegenerative tauopathies, will be discussed in more detail below. 
 
The two main types of strokes are ischemic stroke and hemorrhagic stroke. The 
majority of the strokes are ischemic resulting from a severe reduction in cerebral blood 
flow (Bramlett and Dietrich 2004). As the energy metabolism of the brain is almost 
exclusively dependent on oxidation of glucose, the shortage of oxygen and glucose 
during ischemia leads to rapid depletion of ATP stores. Neurons need a continuous 
supply of energy for instance to maintain the ionic gradients responsible for polarization 
of their plasma membrane. Once the neuron is depolarized, there is influx of calcium 
through the voltage-sensitive channels, and subsequent release of neurotransmitters, 
such as glutamate, at the synaptic region. Also the re-uptake of glutamate is impaired 
due to energy depletion, and thus the level of extracellular glutamate is increased 
(Dirnagl et al. 1999, Bramlett and Dietrich 2004). There is a prominent role for 
glutamate excitotoxicity in ischemia. This has been demonstrated by the protective 
effect of glutamate receptor antagonists in animal models of ischemia (Simon et al. 
1984, Ozyurt et al. 1988, Buchan et al. 1991). The cell death during ischemia occurs by 
both necrosis and apoptosis. In animal models of ischemia, calpain inhibition efficiently 
prevents cell death (Bartus et al. 1994), pointing to an important role for necrosis-
associated phenomena. Morphological analysis also indicates that necrosis indeed is the 
predominant mechanism of cell death after ischemia (Li et al. 1998). However, also 
indicators of apoptosis have been found in ischemia (e.g. translocation of Bax to the 
mitochondria, release of cytochrome c from the mitochondria, increased expression of 
death receptors and their ligands, caspase-3, -8, and -9 induction, and internucleosomal 
DNA fragmentation), and interfering with several mediators of apoptosis has reduced 
the size of the infarct (Ferrer and Planas 2003, Liou et al. 2003). Further, there is also 
morphological evidence indicative of autophagy induction in ischemia (Nitatori et al. 
1995). 
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In chronic neurodegenerative disorders, the underlying cause, as well as the course of 
cell death, is very difficult to evaluate. The amount of mechanistic information that can 
be obtained with human postmortem brain material is limited, and the available material 
often represents the late stages of the disease being contaminated by a significant extent 
of secondary pathology. There is also a shortage of good experimental models. 
Although neurodegenerative disorders constitute a heterogeneous group of diseases, 
there are certain common features in their neuropathology. This suggests that there 
might also be similarities in the mechanisms of cell death. One of the most conspicuous 
features in the neuropathology of neurodegenerative disorders is the presence of large 
protein aggregates either inside the neuronal and/or glial cells, or in the extracellular 
space (Shastry 2003, Ross and Poirier 2004). The main protein components of some of 
these aggregates are presented in table 1. The aggregating proteins generally form long 
filamentous protein polymers often rich in β-sheet conformation, and the proteins also 
contain similar post-translational modifications (ubiquitinylation, phosphorylation, 
oxidation, proteolytic truncation etc.) (Ross and Poirier 2004). It is conceivable that 
these modifications might have a role in the aggregation process. The close association 
of protein aggregation and neuronal degeneration is supported by the fact that mutations 
in the main protein species of the aggregates are the most common causes of 
dominantly inherited rare forms of these degenerative disorders (Ross and Poirier 
2004). However, there is still debate, whether the voluminous protein aggregates are 
actually the cause of cellular degeneration, or may even represent a protective structure 
sequestering the more hazardous but poorly discernible aggregation intermediates (Tran 
and Miller 1999, Ross and Poirier 2004). Whatever the case, research on the upstream 
events of protein aggregation might unravel events that are more closely linked to the 
cell death in neurodegenerative disorders than the presence of the hallmark aggregates 
per se. In addition to protein aggregation, oxidative stress, proteasomal dysfunction, 
excitotoxicity, and mitochondrial injury have been linked with several 
neurodegenerative disorders (Bossy-Wetzel et al. 2004). 
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Table 1. Protein aggregation in some neurodegenerative diseases 
Disease Characteristic pathology Main protein components 
   
AD Neuritic plaques 
Neurofibrillary tangles 
Aβ peptide 
Hyperphosphorylated tau 
   
PD Lewy bodies α-Synuclein 
   
ALS Ubiquitinated inclusions, 
Bunina bodies and hyaline 
bodies 
Superoxide dismutase 1?, 
neurofilaments? 
   
Huntington’s disease Intranuclear inclusions and 
cytoplasmic aggregates 
Huntingtin 
   
Prion diseases Spongiform degeneration, 
amyloid, other aggregates 
Prion protein 
Data from references: (Wood et al. 2003, Ross and Poirier 2004).  
 
Tauopathies are a group of neurodegenerative disorders characterized by the presence of 
intracellular (neuronal and glial) aggregates consisting mainly of filamentous polymers 
of the microtubule-associated protein tau. The most common form of tau-aggregate is 
the neurofibrillary tangle (NFT) (Buee et al. 2000, Lee et al. 2001). Normally tau 
promotes microtubule assembly, stabilizes microtubules, and facilitates the interaction 
of microtubules with other proteins and cellular elements (Buee et al. 2000). The 
sequence of events leading to pathology-associated tau accumulation, filament 
assembly, and formation of inclusions is still poorly understood. One common finding 
in neurodegenerative tauopathies is that tau accumulates in an abnormally 
hyperphosphorylated form. Indeed alterations in the phosphorylation of tau seem to 
occur prior to, or at least concomitant with, aggregation and cellular degeneration 
(Braak et al. 1994). Several kinases (e.g. glycogen synthase kinase 3 and cdk5) have 
been incriminated in the disease-associated tau hyperphosphorylation (Yamaguchi et al. 
1996, Lee et al. 2001). Hyperphosphorylation might detach tau from the microtubules, 
and it could also promote the self-assembly of tau (Buee et al. 2000, Alonso et al. 2001, 
Lee et al. 2001, Avila et al. 2004). Tau polymerization may additionally be promoted by 
other covalent modifications, and by aggregation-promoting intracellular molecules 
(Buee et al. 2000, Avila et al. 2004). A causative role for aberrant tau biology in 
neurodegeneration is suggested for instance by the fact that mutations in the tau gene 
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give rise to a clinically heterogenous group of disorders referred to as frontotemporal 
dementia with parkinsonism linked to chromosome 17 (FTDP-17). The disease-
associated tau mutations have been suggested to promote tau pathology by reducing the 
binding of tau protein to microtubules, by promoting the assembly of tau into filaments, 
or by altering the relative amounts of different tau splice isoforms (Buee et al. 2000, Lee 
et al. 2001). However it should be noted, that there are also families having hereditary 
frontotemporal dementia with linkage to chromosome 17, displaying tau-negative 
inclusions and lacking mutations in the tau gene (van Swieten et al. 2004). 
 
Although there are common features in the neuropathology of tauopathies, these 
disorders differ for instance in the tau phosphorylation patterns, accumulating tau splice 
isoforms, tau filament and inclusion morphologies, affected cell types and brain regions, 
as well as in the clinical manifestation (Buee et al. 2000, Lee et al. 2001, Avila et al. 
2004). AD is the most common tauopathy as well as the most common form of 
dementia. In some rare cases AD is caused by dominantly inherited gene mutations. 
However, the etiology of sporadic AD is poorly understood. Two different types of 
protein aggregates are found in the brains of patients suffering from AD. In addition to 
the intracellular NFTs, there are extracellular amyloid plaques, which are aggregates 
composed mainly of β-amyloid, a peptide enzymatically released from a larger amyloid 
precursor protein (APP) (Odle 2003, Bossy-Wetzel et al. 2004, Mattson 2004). Both 
NFTs and plaques are related to the cognitive deficiency in AD. However, the presence 
of these mature protein aggregates relatively poorly correlates with neuropsychological 
tests of cognitive function. For instance, the density of synapses is far more closely 
associated with the cognitive symptoms (Terry et al. 1991). The fact that only a minor 
proportion of the cells is actually undergoing cell death at any given time in the brains 
of AD patients, makes it difficult to estimate the predominant mechanisms of cell death. 
The biochemical evidence, such as activation of caspase-proteases, point to the 
activation of apoptotic mechanisms in AD (Raina et al. 2003, Dickson 2004, Mattson 
2004). However, there is a shortage of morphological evidence for completion of the 
apoptotic program (Stadelmann et al. 1998, Stadelmann et al. 1999, Raina et al. 2003). 
There is also evidence for elevated lysosomal activity and autophagy in AD, paralleling 
the findings in some other neurodegenerative disorders (Yuan et al. 2003, Nixon et al. 
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2005). Whether these changes in neurodegenerative disorders, such as AD, represent an 
effort to remove potentially hazardous intracellular protein aggregates, or significantly 
contribute to neuronal demise, remains unclear. Nonetheless, the neuronal cell loss in 
AD is likely to be promoted by certain features of the disease e.g. oxidative stress, 
impaired cellular energy metabolism, dysregulated calcium homeostasis, excitotoxicity, 
and inflammation (Danysz et al. 2000, McGeer and McGeer 2003, Mattson 2004). 
 
2.2. The cyclin-dependent kinase 5 (cdk5) 
 
Cdk5 (alternative names: neuronal cdc2-like kinase, tau protein kinase II, PSSALRE) is 
a proline-directed serine/threonine protein kinase originally discovered based on its 
homology with the p34cdc2 (cdk1) kinase (Meyerson et al. 1992). Cdk5 is inactive unless 
bound to cdk5-specific activator proteins p35 or p39 (Lew et al. 1994, Tsai et al. 1994, 
Tang et al. 1995), which represents a common theme in cdk regulation. Generally the 
cyclin-dependent kinases are involved in regulation of cell cycle progression. However 
the predominant expression of cdk5, and more strikingly of the cdk5 activator proteins, 
in post-mitotic neurons immediately led to the suggestion that this kinase possesses 
functions distinct from cell cycle regulation (Hellmich et al. 1992, Tsai et al. 1994, 
Tang et al. 1995). Indeed, cdk5 has been claimed to have a role in the development of 
the nervous system, in learning and memory, in synaptic signaling, and in regulation of 
cell biological events with special importance in the neuronal cells. Functional 
alterations in cdk5 have been suggested to contribute to neuronal cell death in 
neuropathological conditions. Although neurons are the predominant cell type with 
cdk5 activity, also non-neuronal functions for cdk5 have been proposed. The following 
review, however, will concentrate on the biology of cdk5 in the neuronal environment. 
 
2.2.1. Structure of cdk5 and its activator proteins 
 
The human cdk5, p35, and p39 genes are transcribed to single mRNA species encoding 
for proteins of 291, 307 and 367 amino acids, respectively. The primary structure of 
cdk5 protein is highly homologous to some other cyclin-dependent kinases, being 57 % 
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and 60 % identical, respectively, with cdc2 and cdk2 (Meyerson et al. 1992). The p35 
and p39 proteins are 57 % identical (Tang et al. 1995). They do not appear to have 
significant sequence homology with other proteins, apart from the marginal homology 
with the cyclin box employed by various cyclins to interact with their cdk partners (Lew 
et al. 1994, Tsai et al. 1994, Tang et al. 1995). Nevertheless, the overall tertiary 
structure of the large C-terminal globular domain of p35 resembles that of cyclins 
(Tarricone et al. 2001). Both p35 and p39 contain N-terminal myristoylation signals, 
and indeed both proteins are preferentially found attached to membranes (Patrick et al. 
1999, Patzke and Tsai 2002). Also, the N-terminal parts of p35 and p39 are likely less 
tightly structured, and may act in protein-protein interactions (Tarricone et al. 2001). A 
large number of proteins do interact with p35 and/or p39, and it has been suggested that 
the activator proteins might also function as adaptors, targeting cdk5 to large molecular 
complexes, and to the vicinity of its substrates (Lim et al. 2003). 
 
2.2.2. Regulation of cdk5 
 
Regulation of cdk5 takes place at several different levels. There are significant 
alterations in the protein expression of cdk5 and its activator proteins during  neuronal 
differentiation and development of the nervous system, as well as in conditions 
associated with neuronal growth and plasticity. Post-translational mechanisms, such as 
phosphorylation of cdk5, and proteolytic degradation and truncation of cdk5 activators, 
provide more rapid mechanisms for the regulation of cdk5. The role of p35 activator 
protein in cdk5 regulation has been much more extensively studied than that of p39. 
Although there seems to be similarities in the post-translational mechanisms employed 
in the regulation of p35 and p39, there are evident differences e.g. in their temporal and 
spatial expression patterns.  
 
Cdk5, p35, and p39 protein expression.  The protein expression levels of cdk5, p35, and 
p39 are markedly altered during the course of development of the central nervous 
system. Studies performed on rodents have revealed that especially the cdk5 activator 
proteins are highly neuron-specific, and they are first detected when the neurons 
become post-mitotic (Tsai et al. 1993, Tsai et al. 1994, Zheng et al. 1998). The level of 
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cdk5 progressively increases during the development of the nervous system, and 
maximum expression is detected in the adult brain (Kobayashi et al. 1993, Tsai et al. 
1993). Expression of cdk5 is observed throughout the brain with the highest levels 
being found in the hippocampus and mesencephalon (Delalle et al. 1997). Also the p35 
level increases during the course of brain development, peaking at the time of birth. 
However, p35 is downregulated soon after birth, although p35 expression remains high 
in some specific brain regions, such as the hippocampus (Uchida et al. 1994, Tomizawa 
et al. 1996). The expression of p39 differs temporally and spatially from that of p35, 
being low during early development. However, between one to three weeks after birth, 
p39 is highly expressed throughout the brain, whereas in mature brains, p39 expression 
is relatively restricted to the cerebellum (Cai et al. 1997). Subcellularly cdk5 is localized 
to cell bodies in the developing nervous system, whereas in adult rodents, cdk5 is 
predominantly present in the axons, and detectable also in nuclei (Tsai et al. 1993, Ino 
and Chiba 1996, Matsushita et al. 1996, Tomizawa et al. 1996). In cultured cerebellar 
macroneurons cdk5, is especially concentrated at the distal tips of growing axons 
(Pigino et al. 1997). However, p35 mainly locates to the cell bodies and dendrites, and 
axonal p35 is only detectable during the development and soon after birth (Matsushita et 
al. 1996, Tomizawa et al. 1996). Also p39 may be more abundant in the neuronal 
somata and dendrites than in axons of the adult rat brain (Honjyo et al. 1999, Jeong et 
al. 2003). Nevertheless, in cultured neuronal cells at least p35 is also present in the 
growth cones of axons (Paglini et al. 1998). 
 
The presence of cdk5 activator proteins only in post-mitotic neurons suggests that 
neuronal differentiation could activate the expression of these proteins. This is 
supported by upregulation of cdk5, p35, and p39 in cultured cell lines when neuronal 
differentiation is induced by retinoic acid (Fu et al. 2002, Haque et al. 2004, Lee and 
Kim 2004). Also neurotrophic factors stimulate p35 expression in cultured neurons and 
PC12 cells (Tokuoka et al. 2000, Harada et al. 2001). Further, when neurons are 
cultured on laminin, an extracellular matrix protein capable of stimulating axonal 
extension, p35 protein expression, but not p39 expression, is induced. This is associated 
with redistribution of p35 and cdk5 to the axonal growth cones (Pigino et al. 1997, 
Paglini et al. 1998). Additionally, increased neuronal activity and plasticity in vivo have 
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been observed to be associated with upregulation of cdk5 or p35 proteins, e.g. this has 
been detected following chronic electroconvulsive seizures (Chen et al. 2000), during 
kindling progression (Tomizawa et al. 2000), axonal regeneration (Namgung et al. 
2004), associative learning (Fischer et al. 2002), and in conjugation with the adaptive 
changes following chronic cocaine exposure (Bibb et al. 2001a). Changes in the protein 
levels of cdk5 and/or its activators have been also observed during the course of 
neuronal cell death and in various neuropathological conditions, as will be discussed 
later. 
 
Degradation of cdk5 activator proteins.  A common feature in the regulation of cyclin-
dependent kinases is a controlled degradation of the regulatory cyclin proteins by the 
ubiquitin-proteasome pathway at a certain stage of the cell cycle. Although cdk5 mainly 
functions in non-dividing cells, a similar molecular mechanism may be employed in the 
regulation of cdk5. p35 has been observed to be a short-lived protein, which is degraded 
after its ubiquitination by the ubiquitin-proteasome pathway. Phosphorylation of p35 by 
cdk5 appears to favor p35 degradation (Patrick et al. 1998, Saito et al. 2003). The cdk5-
induced degradation of p35 might have an autoregulatory role by providing a means for 
negative feedback regulation of cdk5 activity. Also, the level of p35 phosphorylation, 
and the rate of its proteasomal degradation, is higher in fetal rat brain tissue than in 
adult tissue, findings which suggest that p35 degradation could be developmentally 
regulated (Saito et al. 2003).  
 
Calpain-mediated cleavage of the cdk5 activator proteins.  The cdk5 activator proteins 
p35 and p39 have been found to be cleaved to smaller p25 and p29 fragments, 
respectively, by the calcium-activated calpain-protease (Kusakawa et al. 2000, Lee et al. 
2000, Patzke and Tsai 2002). In accordance with the observed activation of calpain 
during cell death, cleavage of the cdk5 activator proteins is often detected in neurotoxic 
conditions in vitro and in vivo, especially when a prominent calcium influx is known to 
be involved (Kusakawa et al. 2000, Lee et al. 2000, Nath et al. 2000, Patzke and Tsai 
2002). However, activation of calpain is likely not to occur exclusively under conditions 
involving cell death. Calpain has been implicated in remodeling of cytoskeleton-
membrane attachments, in intracellular signal transduction, and in the cell cycle (Goll et 
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al. 2003). Calpain also seems to be participate in long-term potentiation (LTP) (Goll et 
al. 2003), an experimental model of learning and memory involving calcium-dependent 
enhancement of the post-synaptic responses following intense electrical stimulation. 
Indeed, the post-synaptic signaling evoked by the neurotransmitter glutamate induces 
calpain-mediated cleavage of the cdk5 activator proteins during excitotoxic conditions 
(Lee et al. 2000, Patzke and Tsai 2002). However, the occurrence and possible role of 
glutamate-induced cleavage of cdk5 activators in physiological conditions remains to be 
demonstrated. Also the properties of the substrate appear to affect the rate of the 
calpain-mediated cleavage. Cdk5-induced phosphorylation of p35 reduces calpain-
mediated p35-cleavage, again suggesting possible autoregulation. Accordingly, p35 
cleavage is suppressed in fetal brain tissue where the level of p35 phosphorylation is 
high (Saito et al. 2003).  
 
The calpain-mediated cleavage of the cdk5 activator proteins has several types of effects 
on the function of cdk5. The p25 fragment of p35 contains the globular domain 
responsible for cdk5 binding and activation. However, it has lost the less ordered N-
terminal part of p35, which harbors the myristoylation site, and which may mediate the 
interactions between p35 and other proteins (Poon et al. 1997, Patrick et al. 1999, 
Tarricone et al. 2001, Amin et al. 2002). Due to the loss of myristoylation, both p25 and 
p29 are preferentially located in the cytosol, in contrast to p35 and p39, which are 
predominantly membrane bound (Patrick et al. 1999, Kusakawa et al. 2000, Lee et al. 
2000, Patzke and Tsai 2002). Thus the cleavage of the activator proteins results in a 
qualitative change in cdk5 function, and the kinase is allowed access to an alternative 
subset of substrates. Calpain also provokes a quantitative change in cdk5 activity, as 
p25 activates cdk5 more effectively than p35 (Patrick et al. 1999, Amin et al. 2002). 
Further, the p25 and p29 proteins have markedly increased half-lives when compared to 
the uncleaved proteins (Patrick et al. 1999, Patzke and Tsai 2002). It is possible that the 
calpain-cleaved cdk5 activator proteins can escape from the phosphorylation-induced 
proteasomal degradation which has been proposed as a mechanism of negative feedback  
regulation (Patrick et al. 1998). This could lead to constitutive kinase activity. 
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Regulation of cdk5 activity by phosphorylation.  The availability of cyclins is a major 
determinant of cdk activity. However, also phosphorylation is widely employed in the 
regulation of cdks. In this respect, cdk5 possesses some general features of cdk 
regulation, however there are also significant differences. In contrast to the other cdks, 
cdk5 is highly active also in the absence of phosphorylation (Qi et al. 1995). There is 
some controversy on whether phosphorylation of cdk5 by the cdk-activating kinase 
(CAK) on Ser159 at the activating T-loop (corresponding to Thr160 in cdk2 and Thr161 
in cdc2) actually alters cdk5 activity. CAK has been reported either to induce cdk5 
activity in vitro, or to have no effect (Poon et al. 1997, Rosales et al. 2003). Also casein 
kinase I (CKI) has been observed to phosphorylate Ser159 and to stimulate cdk5 
activity (Sharma et al. 1999b). Phosphorylation of cdk5/p35 by CKI has been 
implicated in the transient activation of cdk5 induced by a mGluR agonist in striatal 
slice cultures, although the phosphorylation site in this context has remained 
undetermined (Liu et al. 2001). At least two different kinases phosphorylate cdk5 on 
Tyr15. In contrast to other cdks, phosphorylation at Tyr15 enhances cdk5 activity. c-
Abl, a kinase involved in the development of the nervous system, phosphorylates Tyr15 
of cdk5, and this activity is enhanced by the putative adaptor protein Cables (Zukerberg 
et al. 2000). Phosphorylation of Tyr15 of cdk5 by the fyn kinase is involved in the 
signaling activated by semaphorin-3A, a guidance cue for axons and dendrites (Sasaki 
et al. 2002). Also signaling induced by ephrin-A5, a repulsive axonal guidance cue, 
evokes phosphorylation of cdk5 at Tyr15 by an unidentified kinase (Cheng et al. 2003). 
Phosphorylation of cdk5 at Thr14 by an unidentified kinase purified from the bovine 
thymus has been observed to inhibit cdk5 activity (Matsuura and Wang 1996). 
Nevertheless, phosphorylation of Thr14 has not been demonstrated in vivo. 
Phosphorylation of p35 does not seem to directly affect its ability to activate cdk5 (Saito 
et al. 2003). 
 
Regulation of cdk5 activity by binding of other proteins.  Several inhibitory proteins 
regulate the activity of cell cycle-associated cdks (Obaya and Sedivy 2002). However, 
cdk5 is not affected by the inhibitors modulating the activity of the other cdks (Lee et al. 
1996). Nevertheless, there are some reports suggesting that also cdk5 activity might be 
affected by binding of proteins other than p35 or p39, although this concept is not well 
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established. The present evidence suggests that proteins such as the ribosomal protein 
L34, DNA binding protein dbpA, casein kinase 2, and a previously uncharacterized C42 
protein possess the ability to bind to cdk5 or p35, and inhibit cdk5 activity (Moorthamer 
and Chaudhuri 1999, Moorthamer et al. 1999, Ching et al. 2002, Lim et al. 2004). 
Additionally, a nuclear protein SET appears to activate cdk5/p35 (Qu et al. 2002). The 
molecular mechanisms employed in the regulation of cdk5 are summarized in figure 1. 
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Figure 1. Summary of the molecular mechanisms employed in the regulation of cdk5. 
The figure shows the factors affecting p35/p39 and cdk5, and the proposed effects of 
these factors on protein function. 
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2.2.3. Biological functions of cdk5 
 
A large number of cdk5 substrates are known. In general, the cell biological functions of 
the cdk5 substrates are most often related to the cytoskeleton, synaptic vesicle 
trafficking, cellular adhesion, or to intracellular signal transduction. Via its involvement 
in these cell biological processes, cdk5 is able to participate in fundamental 
neurobiological events ranging from the development of the neuronal architecture to 
synaptic transmission. 
 
Neuronal migration and process outgrowth.  Studies performed on mice lacking cdk5, 
p35, or p39 have established an important role for cdk5 in the proper migration of 
neurons during the development of the nervous system. Mice lacking cdk5 suffer from 
developmental abnormalities related to defective neuronal migration in many brain 
areas including the cerebral cortex, hippocampus and cerebellum (Ohshima et al. 1996, 
Gilmore et al. 1998). In mice lacking p35, the defect in neuronal migration is more 
restricted involving mainly the cerebral cortex (Chae et al. 1997), whereas in mice 
deficient in p39 there are no obvious abnormalities (Ko et al. 2001). The target proteins 
and molecular mechanisms involved in the regulation of neuronal migration by cdk5 are 
still inadequately known. Cdk5 could affect migration by regulating the cytoskeleton, 
cellular adhesion, or the response to guidance cues (Gupta and Tsai 2003). 
 
Several studies suggest that cdk5 is needed for proper outgrowth of neuronal processes 
since prevention of the function of cdk5 significantly reduces the extent of process 
outgrowth in cultured neurons (Nikolic et al. 1996, Pigino et al. 1997). The response to 
some external growth promoting signals may be mediated through induced expression 
of p35 or p39 (Xiong et al. 1997, Paglini et al. 1998, Harada et al. 2001, Desbarats et al. 
2003). In addition, cdk5 is believed to be involved in the regulation of the direction of 
neuritic growth at the growth cones. There is evidence for defective axonal guidance in 
mice lacking p35 (Kwon et al. 1999), and the cellular responses to some guidance cues 
seem to be mediated in a cdk5-dependent manner (Ledda et al. 2002, Sasaki et al. 2002, 
Cheng et al. 2003). 
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Learning and memory.  In mice exposed to stressful conditions, the expression and 
activity cdk5 are induced in the fibers of septohippocampal cholinergic neurons. The 
cdk5 inhibitor butyrolactone I prevents associative learning related to context-dependent 
fear in these conditions (Fischer et al. 2002). Furthermore, mice overexpressing p25 at 
low level display improved performance in some tasks measuring learning and memory 
(Angelo et al. 2003). Cdk5 phosphorylates several substrates that could mediate an 
effect on learning and memory. The LTP-reducing effect of the cdk5 inhibitor 
roscovitine is thought to result from decreased NMDA-evoked currents when cdk5-
mediated phosphorylation of the NR2A subunit of the NMDA receptor is prevented (Li 
et al. 2001).  
 
Regulation of the cytoskeleton.  At the molecular level, many of the neurobiological 
actions of cdk5 are likely to be at least partly mediated through modulation of the 
neuronal cytoskeleton. In neurons, cdk5 has been shown to regulate all of the main 
cytoskeletal elements (microtubules, actin filaments, intermediate filaments) either by 
directly phosphorylating the structural components of the cytoskeleton, or by 
phosphorylating proteins regulating cytoskeletal dynamics. 
 
Cdk5 regulates microtubule dynamics in part via phosphorylation of microtubule-
associated proteins (MAPs). In general, the MAPs bind to microtubules, promote their 
assembly, stabilize them, and organize them into bundles. Tau is a MAP which is 
especially concentrated in axons. Cdk5 has been observed to bind to tau, and to 
phosphorylate it at several different sites (Ishiguro et al. 1992, Baumann et al. 1993, 
Sobue et al. 2000, Lund et al. 2001). In a cell-free system the cdk5-mediated 
phosphorylation of tau reduced the ability of tau to associate with microtubules, and 
prevented tau-induced promotion of microtubule polymerization (Wada et al. 1998). 
Additionally, suppression of cdk5 or p35 expression has been shown to decrease axonal 
elongation as well as to reduce the phosphorylation of MAP1b, another MAP, in the 
distal ends of growing axons of cerebellar macroneurons (Pigino et al. 1997, Paglini et 
al. 1998). Regulation of the microtubule cytoskeleton may be important with respect to 
the effect of cdk5 on neuronal migration. The proteins doublecortin, NUDEL, and focal 
adhesion kinase (FAK) have been suggested as cdk5 target candidates, that might 
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mediate the effect of cdk5 on neuronal migration in a microtubule-dependent manner 
(Niethammer et al. 2000, Sasaki et al. 2000, Xie et al. 2003, Tanaka et al. 2004). 
 
In neurons, an active site of actin filament assembly and disassembly are the growth 
cones, which are critical for elongation of the neurites. Interestingly, cdk5 promotes 
neurite outgrowth, and the cdk5, p35, and p39 proteins are concentrated at the edges of 
neuronal growth cones in the vicinity of actin filaments (Nikolic et al. 1996, Humbert et 
al. 2000). The best studied actin-associated target of cdk5 is the Pak1 kinase (Nikolic et 
al. 1998, Rashid et al. 2001), a Rac1 effector, which is involved in neurite outgrowth 
and growth cone collapse response (Nikolic 2002). 
 
In differentiated neurons, the main type of intermediate filaments are the neurofilaments 
(NFs), which are dynamic components of the axonal cytoskeleton. NFs  are involved in 
the maintenance of the axonal caliber. NF-H and NF-M contain C-terminal KSP-repeat 
motifs that are extensively phosphorylated in vivo, and which are targets for 
phosphorylation by cdk5 (Sun et al. 1996, Sharma et al. 1999a). Phosphorylation of NFs 
by cdk5 alters the intracellular distribution of NFs, and reduces the rate of axonal 
transport of these proteins (Ackerley et al. 2003, Shea et al. 2004). 
 
Regulation of cellular adhesion.  N-cadherin is an adhesion molecule having crucial 
roles during the development of the nervous system. In general, cadherin molecules 
form homophilic contacts with cadherins on adjacent cells, whereas the intracellular 
anchor proteins, catenins, connect these adhesion sites to the intracellular actin-
cytoskeleton. Cdk5-p35 has been observed to associate with the β-catenin–N-cadherin 
complex, and to phosphorylate β-catenin (Kwon et al. 2000, Kesavapany et al. 2001). 
Cdk5 activity decreases β-catenin–N-cadherin interaction and reduces cellular adhesion 
(Kwon et al. 2000). Decreased cdk5 activity evoked by depolarization of hippocampal 
neurons leads to redistribution of β-catenin from the dendritic shafts to the spines, an 
effect which is mimicked by the cdk5 inhibitor roscovitine (Schuman and Murase 
2003). 
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Regulation of synaptic vesicle release and endocytosis.  Cdk5 has been suggested to 
modulate several steps of synaptic vesicle trafficking in the presynaptic terminals. Cdk5 
phosphorylates the P/Q type VSCCs, and thereby inhibits calcium influx into the 
synaptic terminals following depolarization. This reduces the subsequent exocytosis of 
neurotransmitter-containing vesicles (Tomizawa et al. 2002). Cdk5 also binds to and 
phosphorylates Munc-18, which reduces the affinity of Munc-18 for syntaxin 1A, a 
plasma membrane receptor for synaptic vesicles. This has been suggested to allow 
syntaxin 1A to interact with proteins on the synaptic vesicles, and to promote 
neurotransmitter release (Shuang et al. 1998, Fletcher et al. 1999). Thus cdk5 seems to 
inhibit an early step in the synaptic vesicle release, and to augment a later step in the 
process. Synaptic vesicle endocytosis is triggered following dephosphorylation of key 
proteins by the calcium-dependent protein phosphatase, calcineurin. Cdk5 has been 
suggested to participate in the rephosphorylation of some of these proteins 
(amphiphysin I, dynamin I, synaptojanin 1) (Floyd et al. 2001, Tan et al. 2003, 
Tomizawa et al. 2003, Lee et al. 2004). 
 
Post-synaptic signaling.  Binding of dopamine to its receptors results either in 
stimulation or inhibition of cAMP production depending on which dopamine receptor 
type has been activated. A major downstream effector of cAMP is the protein kinase A 
(PKA). In addition to other substrates, PKA phosphorylates the protein phosphatase-1 
(PP-1) inhibitors DARPP-32 (dopamine and cAMP-regulated phosphoprotein, 32 kDa) 
and PP inhibitor-1. This leads to reduced PP-1 activity, and thereby to increased 
phosphorylation of other PKA substrates (Hemmings et al. 1984, Endo et al. 1996). In 
the striatum, cdk5 modulates dopamine signaling by negatively regulating the effects of 
PKA. Under basal conditions, cdk5 phosphorylates DARPP-32, and converts it into an 
inhibitor of PKA (Bibb et al. 1999). Additionally, cdk5 phosphorylates the PP inhibitor-
1, making it a poor substrate for PKA (Bibb et al. 2001b). When dopamine D1 receptors 
are activated, the cdk5 phosphorylation site of DARPP-32 becomes dephosphorylated 
by PP-2A, which abolishes the inhibitory effect of DARPP-32 on PKA (Nishi et al. 
2000). 
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Glutamate-induced cdk5 activation has been suggested to provoke feedback effects on 
post-synaptic glutamate signaling. Cdk5 phosphorylates the NR2A subunit of the 
NMDA class of glutamate receptors (Li et al. 2001). This appears to amplify NMDA-
mediated signaling, since inhibition of cdk5 activity by roscovitine can reduce NMDA 
evoked currents and LTP in hippocampal CA1 neurons (Li et al. 2001). Calpain 
activation might augment the cdk5-mediated effect on the NMDA receptor, as Cdk5-
p25 is more efficient than cdk5-p35 in inducing NR2A phosphorylation and NMDA 
evoked currents in transfected HEK293 cells (Wang et al. 2003). Cdk5 also 
phosphorylates PSD-95, a scaffolding protein that links the NMDA receptors to the 
cytoskeleton and to signaling molecules at the post-synaptic density. The cdk5-mediated 
phosphorylation reduces the self-association of PSD-95. This has been suggested to 
negatively regulate the synaptic clustering of its target proteins, such as NMDA 
receptors (Morabito et al. 2004). 
 
Stimulation of group I mGluRs in neostriatal slice cultures activates a signaling 
pathway involving inositol 1,4,5-triphosphate (IP3)-induced release of calcium from the 
endoplasmic reticulum. This causes calcineurin-mediated induction of CKI, and finally 
transient phosphorylation and activation of cdk5-p35 (Liu et al. 2002). Under these 
conditions, stimulation of mGluRs enhances cdk5-mediated DARPP-32 
phosphorylation as well as calcium influx through VSCCs in a manner dependent on 
cdk5 and DARPP-32 (Liu et al. 2001). 
 
2.2.4. Cdk5 in neuronal cell death and in neuropathological conditions 
 
Cdk5 has important functions throughout the life of neurons, and it may have a role 
during the death of these cells as well. When neurons encounter stressful conditions, 
there are significant changes in cdk5. With respect to human pathological conditions, 
elevated levels of cdk5 or its activator proteins are often detected in affected neurons. 
Also calpain-mediated cleavage of cdk5 activators, which produces increased activity 
and functional alterations in cdk5, has been suggested to occurr in several 
neuropathological conditions. There is an accumulating body of evidence suggesting 
that abnormally intense activation of cdk5 would promote neuronal death. Nevertheless, 
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some studies imply that induction of cdk5 could also support neuronal survival. It is 
conceivable that the preferential effect of cdk5 in stressful conditions might depend on 
factors like intensity, duration, and subcellular location of cdk5 activation, as well as on 
neuronal cell type, and on other factors determining the internal state of the cell. 
 
Alterations in cdk5 during neuronal death and in neuropathological conditions.  Studies 
regarding the regulation of cdk5 in different experimental models of neuronal death 
have revealed a frequent occurrence of calpain-mediated cleavage of cdk5 activators. 
This is consistent with the common involvement of elevated intracellular calcium levels 
in neuronal death. Calpain-mediated cleavage of p35 or p39 has been reported in 
neuronal cell cultures exposed to calcium ionophores, maitotoxin, glutamic acid, β-
amyloid, H2O2, colchicine, or staurosporine (Kusakawa et al. 2000, Lee et al. 2000, 
Nath et al. 2000, Patzke and Tsai 2002, Canudas et al. 2004). In vivo cleavage of p35 
has been detected in malonate-injured rat brains (Nath et al. 2000). Also the protein 
levels of cdk5 and p35 are altered during the process of neuronal cell death. However, 
there is evidence for both elevated (Canudas et al. 2004, Zhang et al. 2004a) and 
reduced (Shirvan et al. 1998, Vartiainen et al. 2002) cdk5 and p35 levels in neuronal 
cultures subjected to toxic conditions. In vivo accumulation of cdk5 and p35 has been 
observed in cell bodies and nuclei during the late stages of apoptotic neuronal death 
(Henchcliffe and Burke 1997, Zhang et al. 1997, Neystat et al. 2001), although this 
might be partially explained by an altered localization of these proteins. 
 
Changes in the regulation of cdk5 take place in several human neuropathological 
conditions, and in experimental models mimicking these disorders. Currently, there are 
no reports investigating cdk5 in human cases affected by ischemic stroke. However, in 
rat brains, elevated cytoplasmic and nuclear immunoreactivities for p35 and cdk5 are 
detected transiently 1 – 3 h after occlusion of the middle cerebral artery  (Hayashi et al. 
1999). Ischemia also causes calpain-mediated cleavage of both p35 and p39 in 
experimental animals (Lee et al. 2000, Nath et al. 2000, Patzke and Tsai 2002).  
 
In AD there is accumulation of cdk5 in neurons harboring NFTs (Yamaguchi et al. 
1996). However, the highest cdk5 levels are detected in neurons displaying lower 
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immunoreactivity for phosphorylated tau and no staining for ubiquitin, which suggests 
preferential expression of cdk5 in neurons with early neurofibrillary degeneration (Pei 
et al. 1998). In transgenic mice mimicking the amyloid pathology of AD, the 
accumulation of cdk5 is a rare event and confined to dystrophic neurites (Tomidokoro et 
al. 2001). Detection of calpain-mediated cleavage of cdk5 activators in human brain 
tissue is markedly hampered by the extensive proteolysis of these proteins during the 
postmortem period (Taniguchi et al. 2001). Thus, it is not surprising that there are 
highly conflicting results on the p25 protein levels in brains of patients with AD 
(Patrick et al. 1999, Takashima et al. 2001, Taniguchi et al. 2001, Yoo and Lubec 2001, 
Tseng et al. 2002, Tandon et al. 2003). However, in AD there is increased 
immunolabeling of NFT-containing neurons with an antibody recognizing the C-
terminus of p35. As immunoreactivity for the N-terminus of p35 is not elevated in 
NFTs, this suggests that it represents the accumulation of the p25 proportion of p35 
(Patrick et al. 1999). In transgenic mice mimicking the amyloid pathology of AD, both 
increased and unaltered levels of p25 have been reported (Otth et al. 2002, Tandon et al. 
2003).  
 
Cdk5 expression is also increased in the motor neurons of patients with ALS. Some, but 
not all, neurons containing accumulated NFs characteristic for ALS also display 
augmented cdk5 immunoreactivity (Nakamura et al. 1997b, Bajaj et al. 1998). 
Additionally, the ALS-mimicking pathology in mice overexpressing mutated 
superoxide dismutase 1 (SOD1) is associated with accumulation of cdk5 in the spinal 
motor neurons. Also increased cleavage of p35 to p25, and elevated cdk5 activity is 
detected in the spinal cord of these animals (Nguyen et al. 2001). Furthermore, cdk5 and 
p35 are found in Lewy bodies of PD and diffuse Lewy body disease (Brion and Couck 
1995, Nakamura et al. 1997a). In mice treated with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) to mimic the pathological alterations of PD, the expression 
of cdk5 is increased in the dopaminergic neurons of the substantia nigra, and also 
elevated cdk5 activity and calpain-mediated cleavage of p35 are detected (Smith et al. 
2003). Additionally, calpain-mediated cleavage of p35 has been reported in rats with 
experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis 
(Schneider et al. 2004). 
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In summary, altered protein expression of p35-cdk5 and/or calpain-mediated cleavage 
of cdk5 activator proteins frequently co-occurs with neuronal death and protein 
accumulation. However, based on these findings alone, it cannot be concluded whether 
the changes in cdk5 contribute to or are a consequence of these processes. 
 
The role of cdk5 in neuronal death.  Several pieces of evidence do suggest that the 
changes in the function of cdk5 in stressful conditions promote the process of neuronal 
cell death. In neuronal cultures, cdk5 inhibitors reduce cell death induced by a wide 
range of neurotoxic insults, such as exposure to β-amyloid, colchicine, the glutathione 
synthase inhibitor buthionine sulfoxamine, or staurosporine, as well as by withdrawal of 
potassium and serum, or lack of neurotrophic factors (Alvarez et al. 1999, Lee et al. 
2000, Jorda et al. 2003, Weishaupt et al. 2003). Also, more specific inhibition of cdk5 
by an antisense oligonucleotide approach, or by overexpression of a polypeptide 
inhibitor of cdk5 (cdk5 inhibitory peptide, CIP), reduces β-amyloid-induced 
upregulation of apoptotic markers and neuronal death (Alvarez et al. 1999, Zheng et al. 
2005). Moreover, overexpression of a dominant-negative mutant form of cdk5 decreases 
glutamate-induced apoptotic changes (Gong et al. 2003). In an experimental model of 
ischemia, cdk5 has been shown to aggravate neuronal cell loss, as inhibition of cdk5 by 
virus-mediated overexpression of dominant-negative cdk5 significantly reduces 
ischemia-induced neuronal death in the hippocampus (Wang et al. 2003). There is also 
evidence suggesting that inhibition of cdk5 can reduce neuronal degeneration in 
experimental animal models of neurodegenerative disorders. Expression of dominant-
negative cdk5 reduces MPTP-induced loss of dopaminergic neurons (Smith et al. 2003). 
Furthermore, cdk5 inhibitors reduce NF and tau phosphorylation as well as loss of 
Purkinje neurons in an animal model of Niemann-Pick type C disease (Zhang et al. 
2004b), a neurodegenerative lysosomal storage disorder. The pathology in these animals 
involves activation of cdk5 (Bu et al. 2002).  
 
Pronounced calpain-mediated cleavage of cdk5 activator proteins has been commonly 
suggested to deregulate cdk5, as calpain evokes increased and prolonged cdk5 activity, 
and releases the active enzyme to the cytosol. Indeed, overexpression of p25 in a 
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neuronal cell line has induced cell death (Hamdane et al. 2003), whereas in neuronal 
cultures, p25 overexpression results in a greater number of condensed nuclei when 
compared to p35 overexpression (Patrick et al. 1999). However, it should not be 
overlooked, that cdk5 can promote neuronal death in vitro also independently of 
calpain-mediated cleavage of cdk5 activators (Weishaupt et al. 2003). 
 
Several downstream mechanisms have been proposed to mediate the neuronal death-
promoting effects of cdk5. Cdk5 might augment neuronal loss by modulating signaling 
systems ubiquitously associated with cell death. Neuronal characteristics do not seem to 
be required for cdk5-mediated cell death, as overexpression of cdk5 and p25 promotes 
apoptotic events in a non-neuronal cell line (Patrick et al. 1999). Indeed, cdk5 has been 
shown to phosphorylate p53, a transcription factor regulating cell cycle progression and 
apoptosis, leading to increased p53 levels and to stimulation of p53-responsive genes, 
such as Bax (Zhang et al. 2002). Cdk5 also downregulates signaling related to 
extracellular signal-regulated kinases 1 and 2 (ERK1/2), which  could promote cell 
death, as activation of ERK1/2 has been suggested to trigger defense responses 
following neuronal injury (Hetman and Gozdz 2004). Cdk5 phosphorylates and thereby 
inhibits the mitogen-activated protein kinase kinase 1 (MEK1), which reduces the 
phosphorylation and the activity of its target ERK1/2 (Sharma et al. 2002). 
Additionally, cdk5 phosphorylates the Ras guanine nucleotide releasing factor 2 
(RasGRF2), which results in decreased Rac activity, and subsequently reduced ERK1/2 
activity through a still uncharacterized mechanism (Kesavapany et al. 2004). Moreover, 
cdk5 phosphorylates and inhibits the activity of the prosurvival transcription factor 
MEF2 (myocyte enhancer factor 2) (Gong et al. 2003). Overexpression of MEF2 which 
is resistant to cdk5-mediated phosphorylation, reduces neuronal cell death induced by 
cdk5-p25 overexpression, H2O2, or glutamate. Some of the effects of cdk5 on cell death 
are mediated by factors that are unique to neuronal cells. In ischemia, there is AMPA 
receptor-evoked activation of cdk5, and subsequent cdk5-mediated phosphorylation of 
the NMDA receptors, which augments NMDA currents and neuronal loss (Wang et al. 
2003). This finding implicates cdk5 in the basic mechanisms of glutamate 
excitotoxicity. The fact that cdk5-specific inhibitors block mitochondrial dysfunction 
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induced by toxic treatments suggests that cdk5 affects relatively early events of cell 
death (Weishaupt et al. 2003). 
 
When regarding the chronic neurodegenerative disorders, cdk5 activation has been 
suggested to affect neuronal degeneration in particular by promoting cytoskeletal 
dysfunction and/or abnormal accumulation of cytoskeletal proteins. The cdk5-induced 
phosphorylation of tau has been frequently proposed to have pathological consequences. 
However, the cdk5-mediated phosphorylation of NFs has been hypothesized even to be 
beneficial by preventing more hazardous cdk5-involving phosphorylation events 
(Nguyen et al. 2001). As mentioned earlier, cdk5 and p35 are found in various 
pathology-associated neuronal inclusions containing abnormally hyperphosphorylated 
tau or NF proteins. Also calpain-mediated cleavage of cdk5 activator proteins has been 
proposed to occur in some neurodegenerative disorders, although detection of this 
phenomenon in human brain material is hampered by postmortem changes. Moreover, 
cdk5 is able to phosphorylate both tau and NF proteins (Ishiguro et al. 1992, Baumann 
et al. 1993, Sun et al. 1996, Sharma et al. 1999a, Lund et al. 2001). In particular, 
calpain-mediated cleavage of p35 has been claimed to affect the potential of cdk5 to 
promote hyperphosphorylation of tau. In vitro and in transfected cell cultures, p25 
appears to be more potent than p35 in promoting cdk5-induced tau phosphorylation 
(Patrick et al. 1999, Hashiguchi et al. 2002). Transgenic mice overexpressing p25 have 
shown alterations in the phosphorylation of tau and NF proteins, although the extent of 
these changes varies significantly (Ahlijanian et al. 2000, Takashima et al. 2001, Bian et 
al. 2002). The most prominent neuropathological effects have been observed in mice 
having postnatally induced overexpression of p25. These animals display neuronal loss, 
increased phosphorylation of NF and tau proteins as well as accumulation of insoluble 
and filamentous tau in association with NFT-like pathology (Cruz et al. 2003). Further, 
introduction of p25 significantly enhances the NFT-like pathology in mice 
overexpressing mutated human tau (Noble et al. 2003). Overexpression of p35 in mice 
results in redistribution of NF proteins, whereas no tau-involving changes are detected 
(Van den Haute et al. 2001). However, no actual comparison of the effects of p25 and 
p35 in transgenic mice has been reported. There is also some evidence suggesting that 
cdk5 might modulate the metabolism related to the formation of extracellular amyloid 
 47
deposits in AD as well. Cdk5 has been reported to phosphorylate APP (Iijima et al. 
2000) and to modify its proteolytic processing (Liu et al. 2003, Ryder et al. 2003, Taru 
et al. 2004), whereas cdk5-mediated phosphorylation of the C-terminal fragment of 
presenilin-1 increases the stability of the protein (Lau et al. 2002).  
 
The neuroprotective role of cdk5.  Some evidence indicates that activation of cdk5 
modulates neuronal signal transduction in a manner that promotes survival. Cdk5 has 
been observed to negatively regulate the c-Jun N-terminal kinase 3 (JNK3), which is a 
mitogen-activated protein kinase (MAPK) believed to promote neuronal cell death e.g. 
in the context of excitotoxicity (Yang et al. 1997). Cdk5 phosphorylates JNK3, leading 
to reduced JNK3 activity and c-Jun phosphorylation in response to ultraviolet 
irradiation (Li et al. 2002). In neuronal cultures prepared from mice lacking cdk5 there 
is elevated JNK3 activity in association with increased sensitivity to apoptosis. 
Moreover, the cdk5 inhibitor roscovitine can prevent the Akt kinase activating and 
neuronal survival promoting effects of neuregulins, a class of epidermal growth factor-
like molecules (Li et al. 2003). Indeed, cdk5 directly phosphorylates the ErbB2 and 
ErbB3 neuregulin receptors. The proposed cdk5-involving mechanisms regulating 
neuronal death and survival are summarized in figure 2. 
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Figure 2. Summary of the proposed cdk5-involving mechanisms regulating neuronal 
death and survival. The figure shows the putative inducers of cdk5 alterations, 
immediate molecular targets of cdk5, the proposed downstream effects, and the final 
outcome. 
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3. AIMS OF THE STUDY 
 
Previous studies have established the crucial role of cdk5 in the regulation of pivotal 
neurobiological events, and implicated deregulation of cdk5 in several 
neuropathological conditions. Detailed knowledge on the regulation of cdk5 will 
promote understanding of basic neurobiology, and strengthen the foundation of studies 
aiming at therapeutic interventions for neurological disorders. Neuronal loss is an 
important feature of several pathological conditions highlighting the need for research 
on the mechanisms of death of these largely irreplaceable cells. The aim of the present 
study was to investigate the regulation of cdk5, especially during the course of neuronal 
cell death, and also to evaluate the possible association between cdk5 and 
phosphorylation of the microtubule-associated protein tau. 
 
The specific aims of the study were:  
 
Study I: To explore how the expression of cdk5 and p35 proteins, as well as cdk5 
activity and tau phosphorylation, are regulated during apoptotic neuronal 
death. 
 
Study II: To investigate how calpain-mediated cleavage of p35 to p25 and 
phosphorylation of tau protein are affected during neuronal cell death 
induced by intracellular calcium concentration-elevating treatments. 
 
Study III: To elucidate the contribution of different ionotropic glutamate receptors on 
the calpain-mediated cleavage of p35 in cultured neurons. 
 
Study IV: To study how p35 phosphorylation can affect the proteolysis of the 
protein. 
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4. MATERIALS AND METHODS 
 
4.1. Hippocampal neuronal cultures 
 
Primary cultures of hippocampal neurons were isolated from 17-days-old Wistar rat 
embryos, and cultured essentially as previously described (Brewer et al. 1993). Pregnant 
rats were anesthetized with CO2 and decapitated. The fetuses were removed and the 
hippocampi were dissected. The hippocampi were incubated for 10 min at +37 °C in 
phosphate-buffered saline (PBS) containing 10 mM glucose and 1 mg/ml bovine serum 
albumin (BSA), which had been supplemented with papain (0.5 mg/ml), DNase I (10 
µg/ml), and MgSO4 (2.4 mM). Thereafter the solution was replaced with PBS-glucose-
BSA supplemented with DNase I (40 µg/ml) and MgSO4, and then the hippocampi were 
triturated, and the suspension was allowed to settle for a few minutes. The supernatant 
was collected, and the trituration was repeated with a fresh solution. The supernatants 
were combined and centrifuged for 5 min at 150 g. The pellet was suspended in 
Neurobasal medium (Gibco) supplemented with 0.5 mM glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 5 % inactivated fetal bovine serum (FBS, 
HyClone). The cells were plated onto poly-D-lysine coated cell culture dishes at a 
density of 60000 cells/ cm2, and maintained at +37 °C in a cell culture incubator in an 
atmosphere of 5 % CO2. On the next day, the medium was replaced with fresh medium 
containing B27 supplement (Gibco) and lacking FBS. When the cells were planned to 
be cultured for 13 days before subjecting to experiments, half of the medium was 
replaced after 8 days of culture.  
 
4.2. Cell culture models of neuronal death 
 
Apoptosis was induced in hippocampal neurons by subjecting the cells to different 
apoptosis-inducing chemicals after 7 – 9 days in culture. The chemicals used included 
the protein phosphatase 1 and 2A inhibitor okadaic acid (10 nM, Calbiochem), the 
topoisomerase II inhibitor etoposide (5 µM, Calbiochem), the calcineurin inhibitor 
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cyclosporin A (10 µM, Calbiochem), and the lipid peroxidation product 4-
hydroxynonenal (HNE, 20 µM, Calbiochem). The incubation times ranged from 6 to 24 
hours. 
 
Treatments of hippocampal neurons with glutamate agonists were performed after 13 
days in culture, as in younger cultures the NMDA receptors are believed to be immature 
(Peterson et al. 1989, Cheng et al. 1999). In study III, also 6-day-old cultures were 
employed to evaluate the alterations in glutamate responses taking place during the 
maturation of neurons in culture. In study III, the glutamate agonists were added 15 min 
after the culture medium had been replaced, whereas in studies II and IV the agonists 
were added into the conditioned medium present on the culture dishes. The glutamate 
agonists used were glutamic acid (40 – 2000 µM, Sigma), NMDA (20 – 2000 µM, 
Sigma), kainic acid (5 – 1000 µM, Sigma), AMPA (100 – 1000 µM, Sigma), and 3,5-
dihydroxyphenylglycine (DHPG, 100 – 1000 µM, Tocris). Exposure times were 30 min 
– 8 h in study II, 30 min in study III, and 60 min in study IV. The experiments with 
calcium ionophores were performed with hippocampal neurons cultured for 13 days, 
and the incubation times were between 40 and 45 minutes. The ionophores included 
ionomycin (1 – 16 µM, Calbiochem) and A23187 (1 – 20 µM, Calbiochem). The 
culture medium was supplemented with 2.5 mM CaCl2 when the incubations with 
glutamate agonists or calcium ionophores were initiated, unless otherwise indicated. 
 
In some experiments, the cultures were preincubated for 10 – 30 min with glutamate 
antagonists or different inhibitors. The glutamate antagonists used were the NMDA 
antagonist MK-801 (10 µM, Tocris), and the non-NMDA antagonists 2,3-dioxo-6-nitro-
1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX, 100 µM, Sigma) and 6-
cyano-7-nitroquinoxaline-2,3-dione (CNQX, 100 µM, Sigma). The inhibitors employed 
were the calpain inhibitor MDL28170 (100 µM, Calbiochem), the L-type VSCC blocker 
nifedipine (200 µM, Sigma), the AMPA receptor desensitization inhibitor cyclothiazide 
(CTZ, 150 µM, Tocris), the kainate receptor desensitization inhibitor concanavalin A 
(Con A, 750 µg/ml, Sigma), the cdk5 inhibitor roscovitine (20 – 40 µM, Calbiochem), 
and the proteasome inhibitor lactacystin (5 µM, Calbiochem).  
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The key findings of the study were observed in at least two separate experiments. The 
reported protein and cell death analyzes were performed on the same dish of cells. 
 
4.3. Preparation and manipulation of protein samples 
 
4.3.1. Preparation of protein samples 
 
The cell cultures were washed with PBS and scraped in protein lysis buffer containing 
20 mM MOPS (3-[N-morpholino]propanesulfonic acid) (pH 7.2), 1 mM MgCl2, 0.3 M 
NaCl, and 0.5 % Nonidet P-40, supplemented with Complete protease inhibitor cocktail 
(Roche). In studies III and IV, and in study II (when indicated) protein phosphatase 
inhibitors (50 mM NaF, 100 µM Na-orthovanadate, 5 mM Na-pyrophosphate, 5 mM 
EDTA) were added into the lysis buffer. The lysates were centrifuged at 13,000g for 20 
minutes (+4 °C), and the supernatants were collected. The protein content of the 
samples was measured employing a DC Protein Assay kit (Bio Rad). When protein 
samples were  isolated from rat brain tissue, the 1-day-old Wistar rat pups were 
sacrificed by decapitation, and the brain tissue (cerebral or cerebellar cortices) was 
homogenized in the protein lysis buffer, and processed as the cell culture samples 
described above.  
 
4.3.2. Phosphatase treatment of protein samples 
 
The protein samples were diluted 6 – 14 fold in the protein lysis buffer lacking protein 
phosphatase inhibitors. In study IV, 5 mM Na-orthovanadate was added into the diluted 
samples to prevent dephosphorylation of p35 occurring efficiently due to endogenous 
phosphatases. The samples were incubated for 1 h at 30 °C with 200-400 U of λ-protein 
phosphatase (λ-PPase, New England BioLabs) in 1× phosphatase buffer containing 50 
mM Tris (pH 7.5), 0.1 mM EDTA, 5 mM dithiotreitol, and 0.01 % Brij 35, 
supplemented with 2 mM MnCl2. A control reaction was carried out in the absence of λ-
 53
PPase. The reaction was terminated by addition of electrophoresis sample buffer 
followed by heating of the samples for 5 min at 95 °C. 
 
4.3.3. ATP treatment of protein samples 
 
Incubation of protein samples with ATP was performed to study the phosphorylation of 
the p35 protein by endogenous kinases in vitro. Rat cortical homogenate was prepared 
in the protein lysis buffer in the absence of phosphatase inhibitors. The homogenate was 
incubated for 20 min – 3 h at 30 °C with 4 mM MgCl2 in the presence or absence of 200 
µM – 1 mM ATP. In some cases 50 mM NaF and 100 µM Na-orthovanadate were 
included into the incubation. The samples were analyzed by immunoblotting with an 
anti-p35 antibody, as will be described later. 
 
4.3.4. Calpain treatment of brain homogenate 
 
Rat cortical brain homogenate was prepared in the protein lysis buffer in the absence of 
phosphatase and protease inhibitors. The effect of protein phosphorylation on calpain-
mediated p35 cleavage was studied by subjecting the brain homogenate first to an ATP 
treatment, followed by incubation for 20 min at 37 °C with 5 mM CaCl2 in the presence 
or absence of purified calpain II (0.5 U, Calbiochem). The reaction was terminated by 
addition of electrophoresis sample buffer followed by heating of the samples for 5 min 
at 95 °C. 
 
4.4. Analysis of cdk5, p35, and tau proteins by immunoblotting 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer 
was added onto equal amounts of protein samples (10-40 µg), and the samples were 
heated for 5 min at 95 °C. The proteins were resolved using 6 – 12 % sodium dodecyl 
sulfate-polyacrylamide gels (SDS-PAGE), and blotted onto Hybond ECL nitrocellulose 
membranes (Amersham). Transfer efficiency and equal loading of the samples was 
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confirmed by staining of the blots with Ponceau S (Sigma). The membranes were 
blocked for 1 h in PBS containing 1 % BSA, 0.2 % non-fat dried milk, and 0.05 % 
Tween-20. Thereafter the blots were subjected for 1 h to primary antibodies diluted in 
the blocking buffer. Primary antibodies were used at the following dilutions: p35 (Santa 
Cruz, C-19), 1:500-1:1000; cdk5 (Santa Cruz, C-8), 1:1000; tau-5 (BioSource, against 
phosphorylation-independent epitope of tau), 1:12000; AT8 (Innogenetics, epitope 
around phosphorylated residue 202 of human tau), 1:2000-1:3000; AT180 
(Innogenetics, tau phosphorylated at residue 231), 1:2000; AT270 (Innogenetics, tau 
phosphorylated at residue 181), 1:12000; pT212 (BioSource, tau phosphorylated at 
residue 212), 1:8000; pS404 (BioSource, tau phosphorylated at residue 404), 1:8000. 
The membranes were washed three times for 5 min in PBS containing 0.05 % Tween-
20, and thereafter incubated for 1 h with peroxidase-conjugated anti-rabbit (Amersham, 
1:2000-1:4000), or anti-mouse (Amersham, 1:2000-1:4000) antibodies diluted in the 
blocking buffer. The membranes were washed as above, and the bound antibodies were 
visualized by enhanced chemiluminescence reaction (Pierce) and film detection 
(Hyperfilm ECL, Amersham). 
 
4.5. Cdk5 activity assay 
 
Cdk5 kinase activity was measured essentially as previously described (Saito et al. 
1998). Fifty µg of protein in 100 µl of protein lysis buffer was incubated with 3 µl of 
anti-cdk5 antibody (Santa Cruz, C-8) for 4 h at +4°C with constant mixing. Twenty µl 
of protein A-Sepharose suspension (Amersham) was added, and the incubation was 
continued overnight. The Sepharose was collected by centrifugation (30 sec, 13000 g), 
and washed twice with washing buffer containing 10 mM MOPS (pH 7.2), 1 mM 
MgCl2, 1 mM EGTA, 5 mM EDTA, 50 mM NaF, 100 M Na-orthovanadate, and 5 mM 
Na-pyrophosphate, and once with assay buffer containing 10 mM MOPS (pH 7.2), and 
1 mM MgCl2. A kinase reaction was carried out by adding 50 µl of assay buffer with 
0.1 mM ATP, 0.4 mg/ml histone H1, and 0.1 mCi/ml [γ-32P]ATP onto the Sepharose, 
and incubating the samples for 30 min at 30 °C. The reaction was terminated by 
addition of electrophoresis sample buffer followed by heating of the samples for 5 
minutes at 95 °C. The proteins were separated employing a 12 % SDS-PAGE gel, and 
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the gel was dried. Radioactivity on the gel was detected by a Storm PhosphorImager 
(Molecular Dynamics), and the pixel volumes of the radioactive histone H1 bands were 
quantified with ImageQuaNT software (Molecular Dynamics).  
 
4.6. Characterization of cell death 
 
4.6.1. Analysis of cell morphology 
 
The cellular morphology was evaluated to obtain an overall impression of the extent of 
neuronal damage. Photographs were taken with a camera attached to an inverted 
microscope immediately prior to collection of protein samples. In study II the 
morphological changes associated with neuronal damage were graded as described in 
figure 3. 
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Figure 3. Grading of neuronal damage by morphological analysis. The morphology of 
neuritic network was graded to be either unchanged (“-“ = no changes whatsoever 
detectable when compared to an untreated control culture), or to have minor changes 
(“+” = local swellings of neurites clearly detectable), moderate damage (“++” = the 
neurites clearly fragmented), or extensive damage (“+++” = even the thickest processes 
fragmented). 
 
4.6.2. Assessment of LDH release 
 
A sample of the cell culture medium was collected to analyze the release of lactate 
dehydrogenase (LDH) to the culture medium upon cell lysis. The medium sample was 
clarified by centrifugation (13000 g, 30 sec), and LDH activity was analyzed with the 
CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega) according to the 
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manufacturer’s instructions. The percentage of cell death was calculated by designating 
LDH release in an untreated control culture as zero percent cell death, and LDH release 
in a detergent lysed culture as 100 percent cell death. 
 
4.6.3. Measurement of cellular ATP levels 
 
The neuronal cultures were washed with PBS, and the cells were lysed in Somatic Cell 
ATP Releasing Reagent (Sigma). The ATP levels in the samples were measured using 
an enzymatic luciferase-based Bioluminescent Somatic Cell Assay kit (Sigma) 
according to the manufacturer’s instructions. 
 
4.6.4. Caspase-3 activity assay 
 
Caspase-3 activity was examined by measuring the amount of a fluorescent product 
released from a synthetic substrate of caspase-3, essentially as suggested by the 
manufacturer of the substrate. In brief, 255 µl of a solution containing 20 mM N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) (pH 7.5), 10 % glycerol, 2 
mM dithiothreitol, and 20 µM Ac-DEVD-AMC (Pharmingen) was added onto 25 µg of 
a protein sample (in 25 µl volume) in the wells of a black 96-well microtiter plate. The 
plate was mixed, and after 60 min in +37 °C, the fluorescence was measured with a 
Victor 1420 Multilabel Counter (Wallac) using 355 nm excitation and 460 nm emission 
wavelengths. 
 
4.6.5. Analysis of αII-spectrin breakdown products 
 
Analysis of the breakdown products of αII-spectrin was used to detect calpain-protease 
activity. αII-Spectrin was analyzed from cell lysates by immunoblotting as described 
above. The αII-spectrin primary antibody (Santa Cruz, C-20) was diluted 1:100, and the 
peroxidase-conjugated anti-goat antibody (Boehringer-Mannheim) was diluted 1:2000. 
Calpain cleaves αII-spectrin from two different sites leading to C-terminal fragments 
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with molecular weights of 145 kDa and 150 kDa. It should be noted that also caspase-3 
can generate a cleavage product with a molecular weight of 150 kDa (Wang 2000). 
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5. RESULTS 
 
5.1. Cdk5 and p35 proteins as well as cdk5 activity and tau phosphorylation are 
downregulated during neuronal apoptosis (I) 
 
Apoptotic cell death was induced in rat hippocampal neuronal cultures by subjecting the 
cells to different apoptosis-inducing compounds. Neuronal damage was evaluated 
microscopically, and activation of the apoptotic cascade was assessed by measuring the 
activity of caspase-3, a central effector caspase. Activity of calpain, a protease activated 
in various necrotic and apoptotic conditions, was detected by examining the level of 
calpain-generated cleavage products of endogenous αII-spectrin. 
 
Okadaic acid induced morphologically visible neuritic damage after 6 hours of 
treatment, whereas the first signs of damaged neuritic network were seen after 12 h in 
neurons treated with etoposide, cyclosporin A, and HNE. All the compounds induced 
caspase-3 activation, ranging from 6 to 20-fold greater activity when compared to an 
untreated control culture (Fig. 1, study I). The level of the 145 kDa calpain-type 
cleavage product of αII-spectrin was low and only detected in cells subjected to 
cyclosporin A or okadaic acid treatment. 
 
The level of p35 protein was reduced with okadaic acid and HNE after 6 h, and with 
etoposide and cyclosporin A after 12 h of treatment (Fig. 2, study I). The p25 levels 
were also reduced early during the course of apoptosis. However, the levels of cdk5 
protein remained relatively constant until becoming reduced at 24 h. HNE provided an 
exception by inducing an early decrease in the cdk5 level. Cdk5 activity was generally 
reduced during the course of cell death. However, the correlation of cdk5 activity with 
p35, p25, and cdk5 protein levels was not obvious in all conditions. We also monitored 
the phosphorylation of tau protein, a substrate of cdk5, during the course of cell death. 
Immunoblotting with the AT8 antibody was used as the phosphorylation-dependent 
epitope of this antibody has been suggested to be especially relevant with respect to 
cdk5-mediated phosphorylation (Patrick et al. 1999, Hashiguchi et al. 2002, Hamdane et 
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al. 2003). Tau phosphorylation was generally slightly reduced during the early phase of 
neuronal death (6 – 12 h), but later phosphorylation was partially restored. Okadaic acid 
induced a substantial increase in tau phosphorylation, probably because tau is a 
substrate of the protein phosphatases inhibited by okadaic acid. An additional tau band 
(47 kDa) was detected in okadaic acid and etoposide treated cells. When a longer 
exposure time of the blot was used, the additional band was observed also in cultures 
subjected to cyclosporin A or HNE (data not shown). The appearance of this band 
peaked at the time of caspase-3 activation. Indeed, the 47 kDa tau isoform may 
represent a caspase cleavage product, as tau is known to be a substrate for caspases 
(Canu et al. 1998, Ko et al. 2000, Krishnamurthy et al. 2000). 
 
5.2. Calpain-mediated cleavage of p35 to p25 during neuronal cell death is not 
associated with tau hyperphosphorylation (II) 
 
Rat hippocampal neuronal cultures were subjected to toxic treatments known to increase 
the concentration of intracellular calcium. The relationship between the calpain-
mediated cleavage of p35, cdk5 activity, and tau phosphorylation was studied during the 
course of cell death. Glutamate induced a prominent cleavage of p35 to p25 already 
after 30 min of treatment, whereas the protein level of cdk5 remained relatively constant 
for 4 h (Fig. 1A, study II). Cdk5 activity was elevated in association with the increased 
p25 levels after a short (30 min – 2 h) glutamate exposure, whereas no increase in cdk5 
activity was detectable after longer incubations (4 – 8 h). As activation of cdk5 has been 
suggested to induce hyperphosphorylation of tau, we also evaluated the relationship 
between cdk5 activity and tau phosphorylation in glutamate treated cells. 
Immunoblotting with a phosphorylation-independent tau antibody (Tau-5) revealed a 
transient appearance of two fast-migrating tau bands. These bands likely represent 
dephosphorylated forms of tau, as similar isoforms were generated when a protein 
sample from cultured neurons was exposed to λ-protein phosphatase (Fig. 1B, study II). 
In agreement with these findings, tau phosphorylation was found to be reduced to a 
varying extent in glutamate treated neurons with five different phosphorylation-
dependent tau antibodies recognizing epitopes phosphorylatable by cdk5 (Fig. 1A, study 
II). The calpain inhibitor MDL28170 prevented the glutamate-induced cleavage of p35 
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to p25, as well as the cleavage of αII-spectrin, another calpain substrate (Fig. 1C, study 
II). However tau phosphorylation remained unaffected suggesting that calpain-mediated 
processes, such as cleavage of p35 to p25, do not contribute to tau phosphorylation in 
these conditions. In general, the first evidence for altered p25 production, cdk5 activity, 
or tau phosphorylation was observed before significant alterations in neurite 
morphology or loss of membrane integrity (LDH release) in glutamate treated cultures 
(Fig. 1A, study II). However, cellular ATP levels displayed a 20 % and 45 % decrease 
in cultures incubated for one hour with 40 µM and 200 µM glutamate, respectively, 
indicating an early disturbance of the energy metabolism.  
 
NMDA, an agonist of the NMDA class of glutamate receptors, also resulted in rapid (30 
min) cleavage of p35 to p25, and decreased tau phosphorylation (Fig. 2, study II). These 
changes also appeared well before any significant changes in neuritic morphology or 
LDH release were apparent (Fig. 2, study II), whereas the amounts of cellular ATP were 
decreased by 19 % and 25 % with 80 and 400 µM NMDA, respectively, when 
compared to an untreated culture after 1 h of incubation. 
 
Cleavage of p35 to p25 was also observed in cultured neurons treated with the calcium 
ionophores ionomycin or A23187 (Fig. 3A and 3C, study II). Decreased tau 
phosphorylation was also detected in these conditions (Fig. 3A and 3D, study II). Again, 
in the cultures treated with the calcium ionophores, the cellular ATP levels were 
decreased (Fig. 3B and 3E, study II). In contrast to glutamate and NMDA treatments, 
the calcium ionophores affected the p25 level and tau phosphorylation only under 
conditions where morphological evidence of cellular damage was apparent (Fig. 3A and 
3D, study II).  
 
5.3. Both NMDA and non-NMDA receptors are able to mediate glutamate-induced 
cleavage of p35 to p25 in cultured neurons (III) 
 
The role of different calcium-permeable ionotropic glutamate receptors in the induction 
of calpain-mediated p35 cleavage was elucidated during the early phase of glutamate 
excitotoxicity in cultured rat hippocampal neurons. A 30-minute treatment of the 
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cultures with glutamate and NMDA, as well as with the non-NMDA receptor agonists 
kainic acid and AMPA, induced prominent cleavage of p35 to p25 (Fig. 1A, study III). 
The term “non-NMDA receptors” is commonly used collectively to refer to the kainate 
and AMPA receptors, as the receptors have significant structural similarity and 
overlapping pharmacological properties. The cleavage of p35 was prevented when the 
cultures were subjected to the glutamate agonists in the presence of the cell-
impermeable calcium chelator ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-
tetraacetic acid (EGTA) (Fig. 2A, study III). This suggests that the p35 cleavage-
inducing calcium mainly originates from the extracellular pool, which is further 
supported by the increased p35 cleavage in the presence of elevated extracellular 
calcium level. Moreover, DHPG, an agonist of the metabotropic group I glutamate 
receptors, did not promote p35 cleavage (Fig. 1B, study III), although these receptors 
have been linked to calcium release from intracellular sources (Sugiyama et al. 1987). 
 
Neuronal responses to glutamate are known to undergo significant changes during 
maturation of neurons in culture (Cheng et al. 1999). Although glutamate, NMDA, and 
kainic acid were all able to induce p35 cleavage to p25 in the 13-day-old hippocampal 
neuronal cultures used above, in the more immature 6-day-old cultures, the effect of 
glutamate was barely detectable, and NMDA had no effect (Fig. 1C, study III). 
Nevertheless, kainic acid caused cleavage of p35 also in these immature cultures. 
 
When studying the contribution of different classes of glutamate receptors on the p35 
cleavage induced by glutamate, it was observed that MK-801, an antagonist of the 
NMDA receptor, prevented the p35 cleavage to p25 in glutamate-treated neurons (Fig. 
2B, study III). However, the non-NMDA antagonists NBQX and CNQX did not block 
the glutamate-induced p35 cleavage. This suggests that the NMDA receptors are the 
predominant mediator of glutamate-induced p35 cleavage under normal culture 
conditions. As expected, the effect of NMDA was blocked by MK-801, whereas the 
action of kainic acid was prevented completely by NBQX and partially by CNQX. Also 
nifedipine, a blocker of the L-type voltage-sensitive calcium channels, partially 
prevented the effect of all of the glutamate agonists studied. 
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Inhibitors of AMPA and kainate receptor desensitization are the most selective 
pharmacological tools available to make a distinction between these non-NMDA 
receptors. When the NMDA receptors in the neuronal cultures were blocked by MK-
801, glutamate alone was inefficient, but with CTZ, a selective inhibitor of AMPA 
receptor desensitization, glutamate induced p35 cleavage to p25 (Fig. 3A, study III). 
This suggests that desensitization of AMPA receptors may prevent glutamate from 
inducing p35 cleavage via AMPA receptor activation in these cultures. Concanavalin A 
(Con A), an inhibitor of kainate receptor desensitization, had a barely detectable effect. 
When a low concentration of the non-NMDA receptor agonist kainic acid was applied 
together with CTZ or Con A, both desensitization inhibitors promoted p35 cleavage 
(Fig. 3B, study III). This implies that the effect of kainic acid on p35 cleavage may be 
mediated through both AMPA and kainate receptors. Also in the absence of agonists, 
CTZ was able to induce p35 cleavage (Fig. 3A and 3B, study III), possibly indicating 
AMPA receptor activation by glutamate constantly released from the cultured neurons. 
Accordingly, previous studies have shown that endogenous glutamate is able to induce 
non-NMDA receptor activity, a property which is strongly enhanced by CTZ (Vignes 
2001). 
 
5.4. Phosphorylation of p35 affects its proteasomal degradation and calpain-
mediated cleavage to p25 (IV) 
 
Protein samples prepared in the absence of phosphatase inhibitors from newborn rat 
cortical or cerebellar tissue, or from cultures of rat hippocampal neurons, contained p35 
protein migrating as a single band in immunoblot (Fig. 1A, study IV). However, when 
protein samples were extracted in the presence of phosphatase inhibitors, p35 displayed 
a mobility shift on SDS-PAGE, leading to a doublet (or triplet) band in the immunoblot. 
This doublet band was converted to a single band when cortical brain lysate was 
incubated with λ-protein phosphatase (Fig. 1B, study IV). Also, incubation of brain 
lysate with ATP resulted in slower electrophoretic migration of p35 (Fig. 1C, study IV). 
These results indicate that the upper band of the p35 doublet represents p35 in a 
phosphorylated form. Treatment of rat hippocampal neuronal cultures with roscovitine, 
an inhibitor of cdk5, led to loss of the phosphorylated upper p35 band in the 
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immunoblot (Fig. 2A, study IV). Roscovitine also inhibited the phosphorylation of p35 
in rat cortical brain homogenate treated with ATP (Fig. 2B, study IV). Collectively the 
above data suggest that p35 is phosphorylated in rat brain tissue to a significant extent, 
and that the main p35-phosphorylating kinase is cdk5. 
 
Previous studies have suggested that phosphorylation of p35 affects its degradation by 
the proteasome in cultured cells (Patrick et al. 1998, Saito et al. 1998). Indeed, the 
proteasome inhibitor, lactacystin, prevented the increased degradation of p35 in 
neuronal cultures treated with the protein phosphatase inhibitor okadaic acid (Fig. 4, 
study IV), consistent with phosphorylation dependent degradation of p35 by the 
proteasome. To study further the p35 phosphorylation events occurring in the presence 
of okadaic acid, brain homogenate from rat cortex was treated with okadaic acid, in 
combination with ATP for 30 min or 3 h. In brain homogenate, ATP alone induced a 
mobility shift in p35 (Fig. 3A, study IV). Addition of okadaic acid together with ATP 
resulted in a p35 band that migrated slower than the band generated by ATP alone. This 
band likely represents p35 phosphorylated at an additional site. On the top of this main 
band there were multiple less intense bands separated from each other by a distance 
corresponding to the phosphorylation induced shift. These multiple bands probably 
represent p35 phosphorylated at a varying number of additional sites. Roscovitine, an 
inhibitor of cdk5, prevented the formation of the multiple p35 bands, as well as 
changing the mobility of the main phosphorylated p35 band in brain homogenate treated 
with ATP and okadaic acid. However, roscovitine did not inhibit all phosphorylations of 
p35. The data suggest that in brain homogenate, ATP and okadaic acid induce p35 
phosphorylation by cdk5, and by a yet unidentified other kinase(s). The decreased 
intensity of the p35 band in these experiments was not due to proteolytic degradation of 
p35, as a phosphatase treatment of brain homogenate after a reaction with ATP and 
okadaic acid restored the intensity of the p35 band (Fig. 3C, study IV).  
 
Calpain is another p35-cleaving protease, and it is responsible for converting p35 to a 
p25 fragment. We investigated whether the phosphorylation of p35 could modulate also 
this cleavage. In brain homogenates, p35 phosphorylation was first induced with ATP 
and okadaic acid, and thereafter the homogenates were treated with calcium to activate 
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endogenous calpain. Addition of calcium to brain homogenate induced the formation of 
p25, which was augmented when purified calpain II was included (Fig. 5B, study IV). 
Extensive phosphorylation of p35 as a result of ATP and okadaic acid treatment led to a 
diminished amount of p25 production. Inhibition of cdk5-dependent phosphorylation by 
roscovitine partially restored the intensity of p25, suggesting that cdk5-mediated 
phosphorylation could be involved in the phosphorylation-dependent reduction of p35 
cleavage. However, in glutamate treated rat hippocampal neuronal cultures, roscovitine 
did not alter the amount of p25 produced (Fig. 5A, study IV). 
 66
6. DISCUSSION 
 
6.1. Regulation of cdk5 during neuronal cell death 
 
Cdk5 has been suggested to regulate several different molecular and cellular factors 
involved in neuronal cell death. Events occurring during the course of neuronal death 
could lead to alterations in cdk5, which might amplify the process. In this study, we 
evaluated the changes in the regulation of cdk5 in primary rat hippocampal neuronal 
cultures subjected to various toxic conditions. Although the objective was to mimic the 
processes of neuronal death occurring in different human neuropathological conditions, 
it should be noted, that the cell culture conditions employed, as well as the resulting 
cellular responses, are likely to differ from the corresponding in vivo events. It is 
obvious that the results obtained with neuronal cell cultures need to be supplemented by 
evidence from other experimental model systems or human brain material, whenever 
possible. The analytical methods used in this study mainly involved different types of 
protein analyses from lysates of cultured neurons. Therefore, the results reflect the 
overall cellular responses during neuronal death, whereas the possible events taking 
place only in a minority of cells, or only in specific subcellular locations may not be 
detected. 
 
Induction of cell death in neuronal cultures.  Neuronal death by apoptosis has been 
implicated in several neuropathological conditions (Friedlander 2003). In this study, 
apoptotic cell death was induced in neuronal cultures by subjecting the cells to different 
types of commonly used pro-apoptotic compounds. Etoposide (an inhibitor of 
topoisomerase II), okadaic acid (an inhibitor of protein phosphatases 1 and 2A), 
cyclosporin A (an inhibitor of calcineurin), and HNE (a product of lipid peroxidation) 
have been observed to induce neuronal cell death showing apoptotic features, such as 
apoptotic nuclear morphology and DNA degradation (Nakajima et al. 1994, Cagnoli et 
al. 1996, McDonald et al. 1996, Kruman et al. 1997, Bezvenyuk et al. 2000, Kaminska 
et al. 2001, Kim et al. 2001, Rabacchi et al. 2004). Induction of caspase-3 activity 
confirms that these compounds did activate the apoptotic cascade in our study. Calpain, 
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a calcium-activated protease more closely associated with necrotic cell death, did not 
appear to be significantly activated in these conditions, as the level of calpain-type 
cleavage products of αII-spectrin remained low. Cell death was also induced by treating 
cultured neurons with compounds known to evoke prominent calcium influx, i.e. 
calcium ionophores and glutamate agonists. Glutamate excitotoxicity is believed to be 
involved in neuronal loss in both acute and chronic neuropathological conditions 
(Lipton and Rosenberg 1994). Glutamate treatment of neuronal cultures provides a good 
tool to study excitotoxicity, however the treatment may more closely model acute 
excitotoxicity than chronic conditions. Although we studied the effects of glutamate 
agonists under excitotoxic conditions, the results can be cautiously considered when 
evaluating the post-synaptic effects of glutamate under physiological conditions. In 
neuronal cultures, glutamate excitotoxicity can be alleviated by inhibiting either calcium 
influx or calpain activation (Choi 1987, Brorson et al. 1995a). We detected calpain-type 
cleavage products of αII-spectrin in glutamate-treated neurons, and their appearance 
could be prevented by a calpain inhibitor, showing activation of calpain under these 
conditions. 
 
Cdk5 and p35 protein levels during neuronal death.  During the course of apoptotic cell 
death, the protein levels of p35, p25, and cdk5 were decreased. A similar tendency was 
observed with several different pro-apoptotic treatments, which suggests that the results 
may reflect a general response to this type of condition. The first signs of decreased p35 
and p25 levels generally appeared relatively early during the course of apoptotic cell 
death i.e. in cells showing no or only minor signs for neuritic damage as characterized 
by morphological evaluation. Okadaic acid provoked a particularly early and prominent 
downregulation of p35 and p25 proteins. However, this likely reflects the effect that p35 
phosphorylation has on the proteasomal degradation of this protein (Saito et al. 1998) 
rather than being a consequence of cell death-associated phenomena. The reduction of 
cdk5 protein expression during apoptosis was mainly restricted to severely damaged 
cells. Accordingly, the cdk5 level was decreased also in neurons profoundly affected by 
glutamate treatment. The mechanisms responsible for the reductions in p35, p25, and 
cdk5 protein levels in these conditions remain unknown. 
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Studies regarding the levels of cdk5 and p35 proteins during experimentally induced 
neuronal death have led to somewhat inconsistent conclusions. The variability of 
changes in these protein levels during neuronal death may be explained for instance by 
dissimilar responses to different types of cell death-inducing stimulus. In cultured 
neurons, the protein levels of cdk5 or p35/p25 have been reported to be decreased due to 
oxidative damage (Shirvan et al. 1998, Egana et al. 2003) or hypoxia/reoxygenation 
(Vartiainen et al. 2002), but the levels are increased following exposure to colchicine 
(Canudas et al. 2004) or staurosporine (Zhang et al. 2004a). In experimental animals, 
the immunoreactivities for cdk5 and p35 are frequently induced in cell bodies and 
nuclei during neuronal death characterized by activation of apoptotic mechanisms 
(Henchcliffe and Burke 1997, Zhang et al. 1997, Neystat et al. 2001). The upregulation 
of cdk5 and p35 is especially detected in cells containing fragmented DNA, or apoptotic 
nuclear changes (Henchcliffe and Burke 1997, Zhang et al. 1997, Neystat et al. 2001) 
suggesting that induction of these proteins may be a late event of apoptosis. Activation 
of gene expression would be a straightforward explanation for the upregulation of the 
proteins in these conditions. The cdk5 and p35 mRNA levels have been determined 
during apoptotic neuronal death in the substantia nigra following a striatal lesion, 
however no alterations were detected (Neystat et al. 2001). Also, following ischemia the 
immunostaining for cdk5 and p35 is increased within 1 h in the neuronal cell bodies and 
nuclei in the affected area (Hayashi et al. 1999) revealing that these kinds of changes 
can occur very rapidly. Since cdk5 protein is normally predominantly expressed in 
axons (Tsai et al. 1993, Ino and Chiba 1996, Matsushita et al. 1996, Neystat et al. 2001), 
the increased levels of cdk5 in neuronal cell bodies could alternatively indicate altered 
intracellular localization of the protein in stressful conditions. This kind of phenomenon 
has been observed to take place during kindling progression (Tomizawa et al. 2000, Cai 
et al. 2001). 
 
Calpain-mediated cleavage of p35 during neuronal death.  Increased cleavage of p35 to 
p25 by the calcium-activated calpain protease has been frequently observed in cultured 
neurons subjected to toxic conditions (Kusakawa et al. 2000, Lee et al. 2000, Nath et al. 
2000, Canudas et al. 2004), and in experimental animal models of neurological 
disorders (Lee et al. 2000, Nath et al. 2000, Nguyen et al. 2001, Bu et al. 2002, Smith et 
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al. 2003). Calpain-mediated p35 cleavage has been suggested to deregulate cdk5, which 
may promote neuronal death (Patrick et al. 1999, Cruz et al. 2003, Hamdane et al. 
2003). However, we detected no signs of p35 cleavage to p25 during apoptotic neuronal 
death, which suggests that p35 cleavage is not an universal event in neuronal apoptosis, 
at least in the early phase in the models studied. The lack of p35 cleavage induction was 
in good agreement with the virtual absence of calpain-type cleavage of αII-spectrin. It is 
possible that calpain-induced deregulation of cdk5 may be restricted to conditions 
where calcium influx is particularly intense. One good candidate as an inducer of p35 
cleavage in both physiological and pathological conditions is the major excitatory 
neurotransmitter glutamate. We observed that glutamate treatment of neuronal cultures 
led to rapid calpain-mediated cleavage of p35 to p25, which preceded the appearance of 
signs for cellular damage, i.e. morphological alterations or leakage of the intracellular 
enzyme LDH. Therefore the calpain-induced changes in the function of cdk5 may be 
able to modulate even the relatively early events of glutamate excitotoxicity. The effect 
of NMDA was similar to that of glutamate, whereas calcium ionophores produced p35 
cleavage only in association with severe neuritic damage. 
 
Pharmacological agents specifically modulating different glutamate receptors constitute 
a promising, although challenging, approach to dampen neuropathological processes. 
This approach requires a detailed knowledge on the role of these receptors in activating 
various downstream signaling pathways. We studied the role of different ionotropic 
glutamate receptors in the induction of calpain-mediated p35 cleavage in more detail 
during the very early phase of glutamate excitotoxicity in neuronal cultures. The 
experiments with different glutamate agonists suggest that both NMDA and non-
NMDA classes of glutamate receptors possess the capability to activate p35 cleavage, in 
a manner dependent on extracellular calcium. In mature neuronal cultures, the 
glutamate-induced p35 cleavage was predominantly mediated via the NMDA receptors, 
although also the L-type VSCCs had a significant role. However, in more immature 
developing cultures, the non-NMDA receptors appeared to have more potential to 
activate p35 cleavage than the NMDA receptors. The changes in the capability of 
NMDA to induce p35 cleavage may be a consequence, for instance, from the changes 
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occurring in NMDA receptor subunit expression during maturation of neurons in culture 
(Cheng et al. 1999). 
 
Both NMDA and non-NMDA receptors are able to mediate glutamate excitotoxicity as 
well as calpain activation. The ionotropic glutamate receptor class preferentially 
producing excitotoxicity may vary e.g. depending on the neuronal type (Brorson et al. 
1995a). The calcium-permeable NMDA receptors have been traditionally considered of 
special importance with respect to excitotoxicity. However, the AMPA and kainate 
receptors can also be calcium-permeable, when a specific subunit of the receptor is 
missing, or present in a rare form produced from unedited mRNA (Dingledine et al. 
1999, Tanaka et al. 2000, Arundine and Tymianski 2003). Additionally, activation of all 
of the ionotropic glutamate receptor classes evoke membrane depolarization, which 
contributes to the secondary opening of the VSCCs. As some signaling molecules are 
physically co-localized with specific glutamate receptors, the actual route of calcium 
influx may be more important than the extent of calcium influx in determining which 
intracellular excitotoxic pathways are activated (Sattler et al. 1998, Arundine and 
Tymianski 2003). 
 
Ischemic damage in experimental animals represents a relevant in vivo model of 
neuronal death, having a significant component of excitotoxicity. In ischemia, 
antagonists of both NMDA and non-NMDA receptors reduce neuronal loss in the 
hippocampus, when administered before or shortly after the insult (Simon et al. 1984, 
Buchan et al. 1991). Recently, the calpain-mediated cleavage of p35 following ischemia 
was found to depend on activation of the non-NMDA receptors (Wang et al. 2003). The 
results of the study are compatible with a sequence of events, where activation of the 
non-NMDA receptors leads to cleavage of p35 to p25, and subsequent cdk5-dependent 
phosphorylation of the NR2A subunit of the NMDA receptor. This enhances the flow of 
ions through the NMDA receptors, and thereby promotes cell death of hippocampal 
CA1 neurons. Downregulation of the calcium permeability-preventing GluR2 subunit of 
the AMPA receptors takes place during ischemia, and this has been suggested to 
promote non-NMDA dependent neuronal death (Pellegrini-Giampietro et al. 1992). 
Interestingly, virus-mediated overexpression of GluR2 reduces neuronal death and p35 
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cleavage during ischemia (Liu et al. 2004). Our results provide further evidence that 
activation of the non-NMDA receptors contributes to p35 cleavage. The data with 
nifedipine suggest that also the L-type VSCCs may be involved in the non-NMDA 
receptor induced p35 cleavage. 
 
Desensitization of the non-NMDA receptors is another feature possibly affecting the 
potential of these receptors to mediate glutamate excitotoxicity (Frandsen and 
Schousboe 2003). For instance, in cerebellar neuronal cultures, the selective 
vulnerability of Purkinje cells to excitotoxicity has been proposed to arise from the 
desensitization properties of the AMPA receptors expressed in these neurons (Brorson 
et al. 1995b). Our experiments with desensitization inhibitors of non-NMDA receptors 
revealed that the non-NMDA receptor-activated p35 cleavage was mediated via the 
AMPA receptors in the hippocampal neuronal cultures. The results also imply that the 
desensitization properties of AMPA receptors could significantly modulate the role of 
these receptors in the activation of p35 cleavage. 
 
Cdk5 activity during neuronal death.  The cdk5 activity was generally reduced during 
neuronal apoptosis thus paralleling the decreased amounts of cdk5, p35, and p25 
proteins. However, the protein levels appeared to predict the activity of cdk5 only 
partially, possibly due to the involvement of other factors in the regulation of the kinase 
activity. These other factors could involve changes in cdk5 phosphorylation, or altered 
cdk5-p35 complex stability, as previously reported in neurons subjected to stressful 
conditions (Alvarez et al. 2001, Zambrano et al. 2004). In glutamate-treated neuronal 
cultures, the calpain-mediated cleavage of p35 was associated with increased cdk5 
activity. This is consistent with the increased ability of p25 to activate cdk5 when 
compared to p35 (Amin et al. 2002). Nevertheless, following longer incubation periods 
with glutamate (4 – 6 h), the alterations in the cdk5 activity were not closely related to 
the protein levels of p35, p25, and cdk5.  
 
Increased activity of cdk5, or the qualitative changes in the function of cdk5 induced by 
calpain-mediated p35 cleavage, have been suggested to promote the process of neuronal 
cell death. Our data imply that glutamate could be a potent activator of cdk5-involving 
 72
mechanisms of neuronal death. However, it is difficult to evaluate the significance of 
decreased cdk5 activity detected during the process of neuronal apoptosis. It can be 
hypothesized that the decline in the activity of cdk5 during neuronal apoptosis could 
reduce the ability of cdk5 to support critical neuronal functions.  
 
6.2. Regulation of p35 proteolysis by phosphorylation 
 
Previous studies suggest that p35 is a phosphoprotein (Lew et al. 1994, Tsai et al. 1994). 
In contrast to phosphorylation of cdk5, phosphorylation of p35 does not seem to 
influence its ability to activate cdk5 (Saito et al. 2003). Phosphorylation of cyclins often 
regulates the degradation of these proteins (Obaya and Sedivy 2002). Accordingly, p35 
phosphorylation could affect the function of cdk5 by modulating the proteolysis of p35. 
 
We analyzed p35 phosphorylation by monitoring the phosphorylation-induced 
retardation in the electrophoretic mobility of the protein by immunoblotting. A 
significant proportion of p35 was detected in a phosphorylated state in the cerebral 
cortex and cerebellum of newborn rats as well as in hippocampal neuronal cultures. The 
phosphorylation of p35 in neuronal cultures and in ATP-treated brain homogenates was 
sensitive to roscovitine, which is a selective inhibitor of cdk5, cdc2, and cdk2 (Meijer et 
al. 1997). As the expression of the cell cycle-associated cyclin-dependent kinases cdc2 
and cdk2 become downregulated during neuronal differentiation (Hayes et al. 1991, 
Freeman et al. 1994, Shirvan et al. 1998, Courtney and Coffey 1999), the roscovitine-
sensitive kinase responsible for p35 phosphorylation in these conditions is most likely 
to be cdk5. This is also supported by the observations showing phosphorylation of p35 
in vitro by purified cdk5 (Lew et al. 1994, Tsai et al. 1994, Saito et al. 2003). 
 
Previously p35 has been found to be ubiquitinated, and degraded in a manner dependent 
on phosphorylation of p35, and on the proteasome (Patrick et al. 1998). In cultured 
neurons the protein phosphatase inhibitor, okadaic acid, induces degradation of p35 
(Saito et al. 1998). This can be prevented by a proteasome inhibitor consistent with 
phosphorylation-dependent degradation of p35 by the proteasome. Our data with 
hippocampal neuronal cultures treated with okadaic acid in the presence of lactacystin 
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confirm this finding. The cdk5-mediated phosphorylation of p35 has been suggested to 
promote proteasomal degradation of p35 (Patrick et al. 1998). However, the finding that 
a significant proportion of p35 exists in a cdk5-phosphorylated state in cultured 
neurons, may indicate that phosphorylation of p35 by cdk5 alone is not a sufficient 
signal for proteasomal degradation of p35. With respect to the p35 degradation-
promoting effect of okadaic acid, this may be caused by additional phosphorylation of 
p35 by another kinase. In ATP-treated brain homogenate, okadaic acid induced 
phosphorylation of p35 at two sites, whereas ATP alone caused p35 phosphorylation at 
one site only. One of these two sites is likely phosphorylated by cdk5, whereas the other 
site appears to be phosphorylated by an unknown roscovitine-insensitive kinase. 
Phosphorylation of p35 by these kinases could provide a means to regulate p35 
proteolysis, and thereby the function of cdk5, in physiological situations. Aberrations in 
the ubiquitin-proteasome system have been implicated in  neurodegenerative disorders, 
such as PD and AD (Ciechanover and Brundin 2003). Currently there are no reports 
indicating that the proteasomal dysfunction in these disorders would be associated with 
a general accumulation of p35. Nevertheless, the proteasomal alterations might 
specifically delay the degradation of the phosphorylated p35 species, thereby affecting 
the possible regulation of cdk5 involving p35 phosphorylation. 
 
We also studied the effect of p35 phosphorylation on the calpain-dependent cleavage of 
p35 to p25. In brain homogenate, phosphorylation of p35 induced by pre-incubation 
with ATP and okadaic acid reduced the amount of calcium-activated calpain-dependent 
cleavage of p35. The cdk5 inhibitor roscovitine partially prevented the effect of the 
phosphorylation reaction on the calpain-mediated p35 cleavage. However, roscovitine 
did not affect the calpain-mediated cleavage of p35 induced by glutamate in neuronal 
cultures. Based on these results, phosphorylation of p35 can reduce its calpain-mediated 
cleavage, whereas the role of cdk5-dependent p35 phosphorylation in this process 
remains elusive. The study by Saito et al. (2003) confirms that phosphorylation of p35 
indeed reduces the calpain-mediated cleavage of p35 in vitro, and provides additional 
evidence for a role for cdk5-induced p35 phosphorylation in this process. Their data 
further suggest that phosphorylation and proteolysis of p35 is developmentally 
regulated. p35 in fetal rat brains was highly phosphorylated and susceptible to 
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proteasomal degradation, whereas in adult brains p35 was less phosphorylated and more 
readily cleaved by calpain. Thus the developmental alterations in the phosphorylation of 
p35 may switch the regulation of cdk5 to a different mode. The authors also hypothesize 
that the age-dependent susceptibility of p35 to calpain-mediated cleavage may be 
related to age-dependent neuronal cell death in neurodegenerative diseases. 
 
6.3. The relationship between cdk5 and tau phosphorylation 
 
Cdk5 has been hypothesized to induce tau hyperphosphorylation under severe 
conditions, in particular following calpain-mediated cleavage of the p35 activator 
protein (Patrick et al. 1999, Ahlijanian et al. 2000, Lee et al. 2000, Nath et al. 2000, 
Cruz et al. 2003). For this reason, we monitored also the phosphorylation of tau protein 
in association with cdk5 during experimentally induced death of cultured neurons. 
Apoptotic neuronal death resulted in generally decreased p35, p25, and cdk5 protein 
levels and cdk5 activity, which was associated with reduced phosphorylation of the tau 
protein. However, tau phosphorylation was decreased also during glutamate 
excitotoxicity, despite of the concomitant calpain-mediated cleavage of p35 to p25, and 
increased cdk5 activity. In principle, a minor effect of the elevated cdk5 activity on tau 
phosphorylation could have been masked by other concurrent changes occurring in 
these conditions. Nevertheless, inhibition of calpain in glutamate-treated neurons had no 
effect on tau phosphorylation, which suggests that calpain-activated processes, i.e. p35 
cleavage to p25, do not contribute to tau phosphorylation. Thus the changes in the 
regulation of cdk5 during neuronal death do not invariably reflect the phosphorylation 
status of tau. 
 
Studies regarding tau phosphorylation during neuronal death in culture have produced 
highly inconsistent results. For instance, treatment of cultured neurons with glutamate 
agonists or calcium ionophores has resulted in both increased (Mattson 1992, Sindou et 
al. 1994) and decreased (Davis et al. 1995, Fleming and Johnson 1995, Saito et al. 1995, 
Adamec et al. 1997, Hull et al. 1999, Lorio et al. 2001, Takashima et al. 2001) 
phosphorylation of tau. Although these inconsistent results may be partially explained 
by the different experimental approaches employed, it seems that tau 
 75
hyperphosphorylation is not an general event in neuronal death. The molecular 
mechanisms leading to reduced tau phosphorylation during apoptotic and excitotoxic 
neuronal death in our study remain elusive. At least during glutamate excitotoxicity, the 
changes in tau phosphorylation occurred irrespective of the alterations in cdk5. Other 
investigators have reported that inhibitors of the calcium-dependent protein phosphatase 
calcineurin prevent dephosphorylation of tau occurring in neurons treated with NMDA, 
or with a calcium ionophore (Fleming and Johnson 1995, Saito et al. 1995). Activation 
of calcineurin could have taken place in the conditions used in our study, especially in 
the neuronal cultures treated with glutamate agonists or calcium ionophores. 
 
Our results showing dephosphorylation of tau protein concomitantly with calpain-
mediated cleavage of p35 to p25 are in apparent conflict with the hypothesis that 
activation of p35 cleavage during neurotoxic conditions would invariably lead to cdk5-
mediated tau phosphorylation. That hypothesis is mainly based on the following 
findings. First, p35 cleavage frequently takes place in various cell culture and in vivo 
conditions involving neuronal death (Kusakawa et al. 2000, Lee et al. 2000, Nath et al. 
2000, Nguyen et al. 2001, Bu et al. 2002, Smith et al. 2003). Second, p25 is more 
efficient than p35 in activating cdk5-mediated tau phosphorylation in vitro, in 
transfected cell cultures, and in transgenic animals (Patrick et al. 1999, Ahlijanian et al. 
2000, Hashiguchi et al. 2002, Cruz et al. 2003, Hamdane et al. 2003). However, the 
evidence suggesting that the calpain-mediated cleavage of the endogenous p35 during 
neuronal death would indeed cause an increase in tau phosphorylation is weak. Our 
findings indicate that this gap in the current knowledge may be significant. The cellular 
effects of overexpressed p25, and p25 released from the endogenous p35, could be 
different for a number of reasons. For instance, overexpressed proteins may be produced 
in an unphysiologically high amount, in an abnormal subcellular location, or in the 
absence of other calcium-activated processes. Nevertheless, cleavage of endogenous 
p35 has been observed in association with increased phosphorylation of tau in some 
experimental animal models of neurological disorders (Nath et al. 2000, Nguyen et al. 
2001, Bu et al. 2002, Smith et al. 2003, Wang et al. 2003). Cdk inhibitors reduce tau 
phosphorylation in some of these models (Smith et al. 2003, Wen et al. 2004, Zhang et 
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al. 2004b), however the contribution of cdks other than cdk5 to tau phosphorylation in 
these conditions is a significant possibility.  
 
The hypothesis regarding the role p25 in cdk5-mediated in tau hyperphosphorylation 
may require updating. Based on the overexpression models, p25 may indeed possess a 
greater potential than p35 to induce tau phosphorylation. Nevertheless, the calpain-
mediated cleavage of the endogenous p35 as such may not be sufficient to activate tau 
phosphorylation. It is possible that in neurodegenerative tauopathies there could be 
some additional factors affecting cdk5, tau, or other cellular elements in such a manner 
that the calpain-dependent cdk5-mediated effect on tau phosphorylation would be 
augmented. This kind of additional factors could be involved for instance in the p25-
cdk5-mediated phosphorylation of tau detected in neurons exposed to β-amyloid. It was 
recently reported, that p35 and p25 as such evoke tau phosphorylation in a comparable 
manner in cultured neurons overexpressing these proteins. However, in the context of 
amyloid toxicity, there was a striking increase in tau phosphorylation, that could be 
prevented by specifically inhibiting the function of p25-cdk5 (Zheng et al. 2005). One 
largely neglected possibility is that cdk5-mediated hyperphosphorylation of tau could 
take place in a manner completely independent of the calpain-mediated cleavage of 
cdk5 activators. Further studies will be required to resolve these issues. 
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7. CONCLUSIONS 
 
The aim of the present study was to investigate the regulation of cdk5, especially during 
neuronal cell death, and to evaluate the possible association between cdk5 and 
phosphorylation of the tau protein. The following conclusions can be drawn: 
 
1. Apoptosis induced in rat hippocampal neuronal cultures by different pro-apoptotic 
stimuli is associated with reduced protein levels of p35, p25, and cdk5, as well as 
with decreased cdk5 activity and tau phosphorylation. 
 
2. During cell death induced by glutamate, NMDA, and calcium ionophores in 
cultured neurons, there is prominent calpain-mediated cleavage of p35 to p25. 
Although this is associated with increased cdk5 activity, at least in the glutamate-
treated neurons, the phosphorylation of tau protein is concomitantly reduced. 
 
3. Calpain-mediated cleavage of p35 to p25 can occur downstream of activation of 
both NMDA and non-NMDA classes of glutamate receptors. The NMDA receptors 
predominantly mediate the effect of glutamate in the cultured hippocampal neurons. 
Functional variation in the glutamate receptors related for instance to changes 
occurring during neuronal maturation, or to differential desensitization properties, 
may determine the potential of different receptor classes to induce p35 cleavage. 
 
4. A significant proportion of p35 is in a phosphorylated state in vivo. Phosphorylation 
of p35 appears to affect its proteolytic degradation by the proteasome, as well as the  
calpain-mediated cleavage of p35 to p25. A roscovitine-sensitive kinase, likely 
cdk5, and another unknown kinase, are able to phosphorylate p35. 
 
In conclusion, this study provides new information on the regulation of cdk5. The 
findings increase the knowledge required to evaluate the possible role of cdk5 in various 
neuropathological conditions. 
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